10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
Q	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2011
OR
¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________________ to ______________
Commission File Number:  001-14273
CORE LABORATORIES N.V.
(Exact name of registrant as specified in its charter)
The Netherlands		Not Applicable
(State of other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)
Herengracht 424
1017 BZ Amsterdam
The Netherlands		Not Applicable
(Address of principal executive offices)		(Zip Code)
(31-20) 420-3191
(Registrant's telephone number, including area code)
None
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes Q  No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes Q  No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Q	Accelerated filer  o	Non-accelerated filer  o	Smaller reporting company  o
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

Yes ¨  No Q

The number of common shares of the registrant, par value EUR 0.02 per share, outstanding at July 28, 2011 was 46,585,151.

CORE LABORATORIES N.V.
FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2011
INDEX
PART I - FINANCIAL INFORMATION
		Page
Item 1.	Financial Statements
	Consolidated Balance Sheets (Unaudited) at June 30, 2011 and December 31, 2010	1
	Consolidated Statements of Operations (Unaudited) for the Three Months Ended June 30, 2011 and 2010	2
	Consolidated Statements of Operations (Unaudited) for the Six Months Ended June 30, 2011 and 2010	4
	Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2011 and 2010	4
	Notes to the Unaudited Consolidated Interim Financial Statements	5
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	32
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	33
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	33
Item 6.	Exhibits	33
	Signature	35

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

CORE LABORATORIES N.V.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

	June 30, 2011			December 31, 2010
ASSETS	(Unaudited)
CURRENT ASSETS:
Cash and cash equivalents	$	24,561		$	133,880
Accounts receivable, net of allowance for doubtful accounts of $3,731 and   $3,396 at 2011 and 2010, respectively	160,208			154,726
Inventories, net	42,508			33,979
Prepaid expenses and other current assets	27,414			26,735
TOTAL CURRENT ASSETS	254,691			349,320
PROPERTY, PLANT AND EQUIPMENT, net	105,126			104,223
INTANGIBLES, net	8,202			8,660
GOODWILL	154,217			154,217
DEFERRED TAX ASSETS, net	6,802			—
OTHER ASSETS	23,195			19,622
TOTAL ASSETS	$	552,233		$	636,042
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	61,331		$	44,710
Accrued payroll and related costs	28,087			28,621
Taxes other than payroll and income	9,116			7,796
Unearned revenue	22,830			20,181
Income tax payable	12,234			21,004
Short-term debt – Senior Exchangeable Notes	89,747			147,543
Other accrued expenses	12,753			9,498
TOTAL CURRENT LIABILITIES	236,098			279,353
DEFERRED COMPENSATION	24,001			21,241
DEFERRED TAX LIABILITIES, net	—			2,198
OTHER LONG-TERM LIABILITIES	37,749			32,046
COMMITMENTS AND CONTINGENCIES	—			—
EQUITY COMPONENT OF SHORT-TERM DEBT – SENIOR EXCHANGEABLE NOTES	2,183			8,864
EQUITY:
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding	—			—
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 49,739,912 issued and 46,483,989 outstanding at 2011 and 49,739,912 issued and 45,521,186 outstanding at 2010	1,397			1,397
Additional paid-in capital	—			—
Retained earnings	459,634			536,991
Accumulated other comprehensive income (loss)	(6,055		)	(6,207		)
Treasury shares (at cost), 3,255,923 at 2011 and 4,218,726 at 2010	(205,913		)	(242,690		)
Total Core Laboratories N.V. shareholders' equity	249,063			289,491
Non-controlling interest	3,139			2,849
TOTAL EQUITY	252,202			292,340
TOTAL LIABILITIES AND EQUITY	$	552,233		$	636,042

The accompanying notes are an integral part of these consolidated financial statements.

1

CORE LABORATORIES N.V.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

	Three Months Ended
	June 30,
	2011			2010
	(Unaudited)
REVENUE:
Services	$	169,756		$	153,010
Product sales	56,029			45,892
Total Revenue	225,785			198,902
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below	112,001			96,411
Cost of product sales, exclusive of depreciation expense shown below	40,272			32,506
General and administrative expenses	9,757			9,211
Depreciation	5,507			5,430
Amortization	298			336
Other expense, net	147			1,288
OPERATING INCOME	57,803			53,720
Loss on exchange of Senior Exchangeable Notes	210			—
Interest expense	2,499			4,114
Income before income tax expense	55,094			49,606
Income tax expense	14,710			15,244
Net income	40,384			34,362
Net income (loss) attributable to non-controlling interest	(67		)	146
Net income attributable to Core Laboratories N.V.	$	40,451		$	34,216
EARNINGS PER SHARE INFORMATION:
Basic earnings per share attributable to Core Laboratories N.V.	$	0.88		$	0.77
Diluted earnings per share attributable to Core Laboratories N.V.	$	0.83		$	0.71
Cash dividends per share	$	0.25		$	0.06
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	45,945			44,651
Diluted	48,662			47,957

The accompanying notes are an integral part of these consolidated financial statements.

2

CORE LABORATORIES N.V.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

	Six Months Ended
	June 30,
	2011			2010
	(Unaudited)
REVENUE:
Services	$	322,870		$	296,452
Product sales	109,648			90,787
Total Revenue	432,518			387,239
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below	212,733			191,768
Cost of product sales, exclusive of depreciation expense shown below	76,290			62,737
General and administrative expenses	19,281			15,591
Depreciation	11,047			10,849
Amortization	589			671
Other (income) expense, net	(1,724		)	490
OPERATING INCOME	114,302			105,133
Loss on exchange of Senior Exchangeable Notes	839			—
Interest expense	4,859			8,173
Income before income tax expense	108,604			96,960
Income tax expense	22,228			30,312
Net income	86,376			66,648
Net income (loss) attributable to non-controlling interest	(365		)	227
Net income attributable to Core Laboratories N.V.	$	86,741		$	66,421
EARNINGS PER SHARE INFORMATION:
Basic earnings per share attributable to Core Laboratories N.V.	$	1.90		$	1.48
Diluted earnings per share attributable to Core Laboratories N.V.	$	1.77		$	1.40
Cash dividends per share	$	0.50		$	0.12
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	45,587			44,743
Diluted	48,942			47,396

The accompanying notes are an integral part of these consolidated financial statements.

3

CORE LABORATORIES N.V.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Six Months Ended
	June 30,
	2011			2010
	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	86,376		$	66,648
Adjustments to reconcile net income to net cash provided by operating activities:
Net (recovery) provision for doubtful accounts	40			811
Provisions for inventory obsolescence	357			298
Equity in earnings of affiliates	(117		)	(239		)
Stock-based compensation	5,923			3,836
Depreciation and amortization	11,636			11,520
Non-cash interest expense	4,144			7,735
(Gain) loss on sale of assets	(138		)	8
Gain on insurance recovery	(779		)	—
Loss on exchange of Senior Exchangeable Notes	839			—
Realization of pension obligation	152			171
(Increase) decrease in value of life insurance policies	(685		)	765
Deferred income taxes	(10,735		)	(8,822		)
Changes in assets and liabilities:
Accounts receivable	(5,627		)	(4,618		)
Inventories	(8,886		)	(1,876		)
Prepaid expenses and other current assets	1,055			23,896
Other assets	(623		)	(540		)
Accounts payable	8,639			6,519
Accrued expenses	(2,080		)	7,698
Other long-term liabilities	8,463			(2,450		)
Net cash provided by operating activities	97,954			111,360
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	(11,984		)	(12,696		)
Patents and other intangibles	(132		)	(142		)
Business Acquisitions	—			(9,000		)
Proceeds from sale of assets	171			125
Proceeds from insurance recovery	884			—
Premiums on life insurance	(1,243		)	(921		)
Net cash used in investing activities	(12,304		)	(22,634		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt borrowings	(64,477		)	—
Stock options exercised	241			295
Excess tax benefits from stock-based compensation	2,289			798
Debt financing costs	(1,094		)	—
Settlement of warrants	(57,777		)	—
Non-controlling interest - contributions	895			—
Non-controlling interest - dividend	(240		)	(181		)
Dividends paid	(22,709		)	(5,375		)
Repurchase of common shares	(52,097		)	(91,686		)
Net cash used in financing activities	(194,969		)	(96,149		)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(109,319		)	(7,423		)
CASH AND CASH EQUIVALENTS, beginning of period	133,880			181,045
CASH AND CASH EQUIVALENTS, end of period	$	24,561		$	173,622

The accompanying notes are an integral part of these consolidated financial statements.

4

CORE LABORATORIES N.V.

NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1.  BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements include the accounts of Core Laboratories N.V. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP") for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP and should be read in conjunction with the financial statements and the summary of significant accounting policies and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2010.

Core Laboratories N.V. uses the equity method of accounting for investments in which it has less than a majority interest and over which it does not exercise control. Non-controlling interest has been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned.  In the opinion of management, all adjustments considered necessary for the periods presented have been included in these financial statements.  Furthermore, the operating results presented for the three and six months ended June 30, 2011 may not necessarily be indicative of the results that may be expected for the year ended December 31, 2011.

Core Laboratories N.V.'s balance sheet information for the year ended December 31, 2010 was derived from the 2010 audited consolidated financial statements but does not include all disclosures in accordance with U.S. GAAP.

Certain reclassifications were made to prior period amounts in order to conform to the current period presentation.  These reclassifications had no impact on the reported net income for the three and six month periods ended June 30, 2011.

References to "Core Lab", "we", "our" and similar phrases are used throughout this Quarterly Report on Form 10-Q and relate collectively to Core Laboratories N.V. and its consolidated subsidiaries.

2.  INVENTORIES

Inventories consist of the following (in thousands):

	June 30, 2011		December 31, 2010
	(Unaudited)
Finished goods	$	31,843	$	24,476
Parts and materials	8,716		6,727
Work in progress	1,949		2,776
Total inventories, net	$	42,508	$	33,979

We include freight costs incurred for shipping inventory to customers in the Cost of Sales line of the Consolidated Statements of Operations.

3. GOODWILL AND INTANGIBLES

We account for intangible assets with indefinite lives, including goodwill, in accordance with the applicable accounting guidance, which requires us to evaluate these assets for impairment annually, or more frequently if an indication of impairment has occurred.  Based upon our most recent evaluation, we determined that goodwill is not impaired.  We amortize intangible assets with a defined term on a straight-line basis over their respective useful lives.

In 2010, we acquired fracture diagnostics assets for $9.0 million in cash.  The acquisition was recorded in the Production Enhancement business segment and resulted in an increase of $5.6 million in goodwill and an increase of $3.2 million in intangible assets.  The intangible assets will be amortized over a period of 36 to 60 months.

5

4.  DEBT

Debt is summarized in the following table (in thousands):

	June 30, 2011			December 31, 2010
	(Unaudited)
Senior exchangeable notes	$	91,930		$	156,407
Discount on senior exchangeable notes	(2,183		)	(8,864		)
Net senior exchangeable notes	$	89,747		$	147,543

In 2006, Core Laboratories LP, an entity 100% indirectly owned by Core Laboratories N.V., issued $300.0 million aggregate principal amount of Senior Exchangeable Notes (the "Notes") which are fully and unconditionally guaranteed by Core Laboratories N.V. and mature on October 31, 2011.  The Notes bear interest at a rate of 0.25% per year paid on a semi-annual basis.

With the additional amortization of the discount on the Notes, the effective interest rate is 7.48% for the three and six month period ended June 30, 2011, which resulted in additional non-cash interest expense of $1.8 million and $3.9 million for the three months ended June 30, 2011 and 2010, respectively, and $4.0 million and $7.7 million for the six months ended June 30, 2011 and 2010, respectively.  Each Note carries a $1,000 principal amount and is exchangeable into shares of Core Laboratories N.V. common stock under certain circumstances at an exchange price of $45.51 per share, or 21.9738 shares per Note.  Upon exchange, holders will receive cash for the principal amount plus any amount related to fractional shares, and any excess exchange value will be delivered in whole shares of Core Laboratories N.V. common stock at the completion of the valuation period as defined under our Notes agreement.  At June 30, 2011, the Notes were trading at 243% of their face value which is equivalent to $131.5 million of value in excess of the aggregate principal amount. At December 31, 2010, the Notes were trading at 197% of their face value which is equivalent to $151.7 million of value in excess of the aggregate principal amount.  There were 91,930 and 156,407 Notes outstanding at June 30, 2011 and December 31, 2010, respectively.

Under the terms of the Notes, defined criteria were met which allowed the Notes to be early exchanged during the second quarter of 2011, as it was during the first quarter of 2011, and as a result the equity component of the Notes at June 30, 2011 was classified as temporary equity.  This balance combined with the debt amount reflects the amount that could result in cash settlement upon exchange.  We received nine requests to exchange 17,909 Notes which were settled during the second quarter for $17.9 million in cash and 213,936 shares of our common stock, all of which were treasury shares, resulting in a loss of $0.2 million.  We also received five requests during the second quarter to exchange 888 Notes which we will settle during the third quarter upon completion of the requisite holding period per the Note Indenture agreement.

On April 19, 2011, we entered into an agreement for an amended revolving credit facility(the "Credit Facility") that we maintain that allowed for an aggregate borrowing capacity of $300.0 million at June 30, 2011. The Credit Facility also provided an option to increase the commitment under the Credit Facility to $350.0 million, if certain conditions are met.  The Credit Facility bears interest at variable rates from LIBOR plus 1.75% to a maximum of LIBOR plus 2.50%.  Any outstanding balance under the Credit Facility is due in December 2015 when the Credit Facility matures.   Interest payment terms are variable depending upon the specific type of borrowing under this facility. Our available capacity is reduced by outstanding letters of credit and performance guarantees and bonds totaling $14.5 million at June 30, 2011 relating to certain projects in progress.  Our available borrowing capacity under the Credit Facility at June 30, 2011 was $285.5 million.  As of June 30, 2011, we had $17.9 million of outstanding letters of credit and performance guarantees and bonds in addition to those under the Credit Facility.

The terms of the Credit Facility require us to meet certain financial and operational covenants. We believe that we were in compliance with all such covenants at June 30, 2011.  All of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility.

5.  PENSIONS AND OTHER POSTRETIREMENT BENEFITS

We provide a noncontributory defined benefit pension plan covering substantially all of our Dutch employees (the "Dutch Plan") who were hired prior to 2007 based on years of service and final pay or career average pay, depending on when the employee began participating. The benefits earned by the employees are immediately vested.  We fund the future obligations of the Dutch Plan by purchasing investment contracts from a large multi-national insurance company.  The investment contracts

6

are purchased annually and expire after five years at which time they are replaced with new contracts that are adjusted to include changes in the benefit obligation for the current year and redemption of the expired contracts.  We determine the fair value of

these plan assets with the assistance of an actuary using observable inputs (Level 2).  We make annual premium payments to the insurance company, based on each employee's age and current salary.

The following table summarizes the components of net periodic pension cost under this plan for the three and six months ended June 30, 2011 and 2010 (in thousands):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2011			2010			2011			2010
	(Unaudited)						(Unaudited)
Service cost	$	352		$	304		$	687		$	627
Interest cost	454			352			886			728
Expected return on plan assets	(211		)	(111		)	(412		)	(230		)
Amortization of transition asset	(22		)	(22		)	(44		)	(44		)
Amortization of prior service cost	40			40			80			80
Amortization of net loss	84			95			168			189
Net periodic pension cost	$	697		$	658		$	1,365		$	1,350

During the six months ended June 30, 2011, we contributed approximately $1.9 million, as determined by the insurance company, to fund the estimated 2011 premiums on investment contracts held by the Dutch Plan.

We have adopted a non-qualified deferred compensation plan that allows certain highly compensated employees to defer a portion of their salary, commission and bonus, as well as the amount of any reductions in their deferrals under the deferred compensation plan for employees in the United States (the "Deferred Compensation Plan"), due to certain limitations imposed by the U.S. Internal Revenue Code of 1986, as amended (the "Internal Revenue Code").  The Deferred Compensation Plan also provides for employer contributions to be made on behalf of participants equal in amount to certain forfeitures of, and/or reductions in, employer contributions that participants could have received under the 401(k) Plan in the absence of certain limitations imposed by the Internal Revenue Code. Employer contributions to the Deferred Compensation Plan vest ratably over a period of five years. Contributions to the plan are invested in equity and other investment fund assets, and carried on the balance sheet at fair value.  A participant's plan benefits include the participant's deferrals, the vested portion of the employer's contributions, and deemed investment gains and losses on such amounts. The benefits under these contracts are fully vested and payment of benefits generally commences as of the last day of the month following the termination of services except that the payment of benefits for select executives generally commences on the first working day following a six month waiting period following the date of termination.

On a recurring basis, we use the market approach to value certain assets and liabilities at fair value at quoted prices in an active market (Level 1) and certain assets and liabilities using significant other observable inputs (Level 2). We do not have any assets or liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3). Gains and losses related to the fair value changes in the deferred compensation assets and liabilities are recorded in General and Administrative Expenses in the Consolidated Statements of Operations.  The following table summarizes the fair value balances (in thousands):

(Unaudited)			Fair Value Measurement at
			June 30, 2011
	Total		Level 1		Level 2		Level 3
Assets:
Deferred compensation plan trust assets	$	10,156	$	—	$	10,156	$	—
Liabilities:
Deferred compensation plan	$	15,203	$	2,932	$	12,271	$	—

7

			Fair Value Measurement at
			December 31, 2010
	Total		Level 1		Level 2		Level 3
Assets:
Deferred compensation plan trust assets	$	8,802	$	—	$	8,802	$	—
Liabilities:
Deferred compensation plan	$	13,063	$	2,275	$	10,788	$	—

6. COMMITMENTS AND CONTINGENCIES

We have been and may from time to time be named as a defendant in legal actions that arise in the ordinary course of business.  These include, but are not limited to, employment-related claims and contractual disputes or claims for personal injury or property damage which occur in connection with the provision of our products and services.  Management does not currently believe that any of our pending contractual, employment-related, personal injury or property damage claims and disputes will have a material effect on our future results of operations, financial position or cash flow.

7.  EQUITY

During the three months ended June 30, 2011, we repurchased 23,409 of our common shares for $2.3 million. These shares were surrendered to us pursuant to the terms of a stock-based compensation plan in consideration of the participants' tax burdens that may result from the issuance of common shares under that plan. During the six months ended June 30, 2011, we repurchased 574,174 of our common shares for $52.1 million. Included in this total were rights to 29,680 shares valued at $2.9 million that were surrendered to us pursuant to the terms of a stock-based compensation plan in consideration of the participants' tax burdens that may result from the issuance of common shares under that plan. Such common shares, unless canceled, may be reissued for a variety of purposes such as future acquisitions, employee stock awards, exchange of the Notes, or settlement of outstanding warrants.

In February and May 2011, we paid a quarterly dividend of $0.25 per share of common stock.  In addition, on July 12, 2011, we declared a quarterly dividend of $0.25 per share of common stock for shareholders of record on July 22, 2011 and payable on August 22, 2011.

In 2006, we sold warrants on our common shares, which have an exercise price of $61.25 per share, and will settle in January 2012.  The warrant agreement calls for the net value of these warrants to be settled with Core Laboratories N.V. common shares. 

In May 2011, we reached an agreement with the holder of the warrants to accelerate the settlement of 25% of the warrants. This agreement called for the daily settlement of 82,402 warrants using an exercise price which was adjusted based on the daily volume weighted average price. During May and June 2011, we settled 1,648,040 of the outstanding warrants using a calculated exercise price which averaged $59.57 during the period. These settlements resulted in the distribution of 630,744 shares of treasury stock. There was a second agreement entered into during the first week of June 2011 with the holder of the warrants to accelerate the settlement of an additional 25% of the original number of warrants during the months of June and July 2011. During June 2011, we settled 1,565,638 warrants using a calculated exercise price which averaged $60.24 during the period. We had the option to settle this tranche of warrants with cash or shares. These settlements resulted in a distribution of $57.8 million in cash during June 2011 with an additional $8.0 million in cash and 37,692 shares distributed in July 2011.

The following table summarizes our changes in equity for the six months ended June 30, 2011 (in thousands):

8

	Common		Additional Paid-In			Retained			Accumulated Other Comprehensive			Treasury			Non- Controlling			Total
(Unaudited)	Shares		Capital			Earnings			Income (Loss)			Stock			Interest			Equity
December 31, 2010	$	1,397	$	—		$	536,991		$	(6,207	)	$	(242,690	)	$	2,849		$	292,340
Stock options exercised	—		(1,377		)	—			—			1,618			—			241
Stock based-awards	—		307			—			—			5,616			—			5,923
Tax benefit of stock-based awards issued	—		2,289			—			—			—			—			2,289
Repurchase of common shares	—		—			—			—			(52,097		)	—			(52,097		)
Dividends paid	—		—			(22,709		)	—			—			—			(22,709		)
Equity component of short-term debt	—		6,681			—			—			—			—			6,681
Exchange of Senior Exchangeable Notes	—		(5,031		)	(40,311		)	—			43,452			—			(1,890		)
Settlement of warrants	—		(2,869		)	(101,078		)	—			38,188			—			(65,759		)
Non-controlling interest contribution	—		—			—			—			—			895			895
Non-controlling interest dividends	—		—			—			—			—			(240		)	(240		)
Comprehensive income:
Amortization of deferred pension costs, net of tax	—		—			—			152			—						152
Net income (loss)	—		—			86,741			—			—			(365		)	86,376
Total comprehensive income																		86,528
June 30, 2011	$	1,397	$	—		$	459,634		$	(6,055	)	$	(205,913	)	$	3,139		$	252,202

Comprehensive Income

The components of comprehensive income consisted of the following (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2011		2010		2011		2010
	(Unaudited)				(Unaudited)
Net income	$	40,384	$	34,362	$	86,376	$	66,648
Amortization of deferred pension costs, net of tax	76		86		152		171
Total comprehensive income	$	40,460	$	34,448	$	86,528	$	66,819

9

Accumulated other comprehensive income (loss) consisted of the following (in thousands):

	June 30, 2011			December 31, 2010
	(Unaudited)
Prior service cost	$	(793	)	$	(853	)
Transition asset	292			324
Unrecognized net actuarial loss	(5,554		)	(5,678		)
Total accumulated other comprehensive income (loss)	$	(6,055	)	$	(6,207	)

8.  EARNINGS PER SHARE

We compute basic earnings per common share by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common and potential common shares include additional shares in the weighted average share calculations associated with the incremental effect of dilutive employee stock options, restricted stock awards and contingently issuable shares, as determined using the treasury stock method. The

following table summarizes the calculation of weighted average common shares outstanding used in the computation of diluted earnings per share (in thousands):

	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2011	2010	2011	2010
	(Unaudited)		(Unaudited)
Weighted average basic common shares outstanding	45,945	44,651	45,587	44,743
Effect of dilutive securities:
Stock options	23	55	24	56
Contingent shares	68	44	63	37
Restricted stock and other	230	568	274	550
Senior exchangeable notes	1,097	1,823	1,176	1,586
Warrants	1,299	816	1,818	424
Weighted average diluted common and potential common shares outstanding	48,662	47,957	48,942	47,396

In 2006, we sold warrants on our common shares, which have an exercise price of $61.25 per share, and will settle in January 2012.  The warrant agreement calls for the net value of these warrants to be settled with Core Laboratories N.V. common shares. 

Included in the table above are 1,299,000 and 816,000 shares which were added to the share count for the three months ended June 30, 2011 and 2010, respectively, and 1,818,000 and 424,000 shares which were added to the share count for the six months ended June 30, 2011 and 2010, respectively, because the average share price exceeded the strike price of the warrants.  These shares were included in calculating the impact to our dilutive earnings per share for the three and six months ended June 30, 2011 and 2010.

9. OTHER (INCOME) EXPENSE, NET

The components of other (income) expense, net, were as follows (in thousands):

10

	Three Months Ended							Six Months Ended
	June 30,							June 30,
	2011				2010			2011			2010
	(Unaudited)							(Unaudited)
(Gain) loss on sale of assets	$	(75	)		$	39		$	(138	)	$	8
Foreign exchange (gain) loss	(9		)		1,712			(521		)	1,621
Interest income	(30		)		(130		)	(85		)	(142		)
Rents and royalties	(382		)		(218		)	(833		)	(700		)
Gain on insurance recovery	(69		)		—			(779		)	—
Legal entity realignment	711			711	—			711			—
Other, net	1				(115		)	(79		)	(297		)
Total other (income) expense, net	$	147			$	1,288		$	(1,724	)	$	490

During the third quarter of 2010, an office and laboratory facility was damaged by fire, resulting in the loss of the laboratory portion of the building, as well as some of the laboratory equipment.  The final settlement was reached in the first quarter of 2011, which resulted in a gain of $0.8 million.

Foreign exchange (gains) losses by currency are summarized in the following table (in thousands):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2011			2010			2011			2010
	(Unaudited)						(Unaudited)
British Pound	$	44		$	158		$	(47	)	$	416
Canadian Dollar	(124		)	149			(543		)	(236		)
Euro	41			1,619			(25		)	1,589
Mexican Peso	36			(14		)	142			94
Russian Ruble	(24		)	(69		)	(219		)	(15		)
Other currencies, net	18			(131		)	171			(227		)
Total (gain) loss	$	(9	)	$	1,712		$	(521	)	$	1,621

10.  INCOME TAX EXPENSE

The effective tax rates for the three months ended June 30, 2011 and 2010 were 26.7% and 30.7%, respectively.  The effective tax rates for year to date 2011 and 2010 were 20.5% and 31.3%, respectively. Included in income tax expense is the reversal in the six months ended June 30, 2011 of $10.4 million in tax liabilities provided over the period of 2007-2010 as a result of recently concluded audits of prior year returns.  The liability reversal reflects the impact of positions sustained in certain audits.

11.  SEGMENT REPORTING

We operate our business in three reportable segments:  (1) Reservoir Description, (2) Production Enhancement and (3) Reservoir Management.  These business segments provide different services and utilize different technologies.

• Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.

• Production Enhancement: Includes products and services relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.

• Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.

11

Results for these business segments are presented below.  We use the same accounting policies to prepare our business segment results as are used to prepare our Consolidated Financial Statements.  We evaluate performance based on income or loss before income tax, interest and other non-operating income (expense). All interest and other non-operating income (expense) is attributable to the Corporate & Other area and is not allocated to specific business segments. Summarized financial information concerning our segments is shown in the following table (in thousands):

(Unaudited)	Reservoir Description		Production Enhancement		Reservoir Management		Corporate & Other 1			Consolidated
Three Months Ended June 30, 2011
Revenues from unaffiliated customers	$	118,758	$	88,787	$	18,240	$	—		$	225,785
Inter-segment revenues	447		357		595		(1,399		)	—
Segment operating income	26,629		24,500		7,307		(633		)	57,803
Total assets	272,298		208,114		19,146		52,675			552,233
Capital expenditures	4,079		2,499		284		743			7,605
Depreciation and amortization	3,517		1,578		169		541			5,805
Three Months Ended June 30, 2010
Revenues from unaffiliated customers	$	106,528	$	79,717	$	12,657	$	—		$	198,902
Inter-segment revenues	248		419		427		(1,094		)	—
Segment operating income (loss)	25,074		26,152		3,672		(1,178		)	53,720
Total assets	258,759		190,512		14,245		189,145			652,661
Capital expenditures	4,600		720		219		1,002			6,541
Depreciation and amortization	3,523		1,626		166		451			5,766
Six Months Ended June 30, 2011
Revenues from unaffiliated customers	$	226,379	$	170,885	$	35,254	$	—		$	432,518
Inter-segment revenues	816		665		954		(2,435		)	—
Segment operating income (loss)	53,067		47,762		13,971		(498		)	114,302
Total assets	272,298		208,114		19,146		52,675			552,233
Capital expenditures	7,382		3,303		391		908			11,984
Depreciation and amortization	6,999		3,217		349		1,071			11,636
Six Months Ended June 30, 2010
Revenues from unaffiliated customers	$	210,621	$	148,561	$	28,057	$	—		$	387,239
Inter-segment revenues	548		713		715		(1,976		)	—
Segment operating income (loss)	50,215		47,095		9,292		(1,469		)	105,133
Total assets	258,759		190,512		14,245		189,145			652,661
Capital expenditures	9,929		1,392		257		1,118			12,696
Depreciation and amortization	7,030		3,249		324		917			11,520

(1) "Corporate & Other" represents those items that are not directly related to a particular segment and eliminations.

12. CONDENSED CONSOLIDATING FINANCIAL INFORMATION

Core Laboratories N.V. has fully and unconditionally guaranteed all of the Notes issued by Core Laboratories LP in 2006. Core Laboratories LP is an entity 100% indirectly owned by Core Laboratories N.V.

The following condensed consolidating financial information is included so that separate financial statements of Core Laboratories LP are not required to be filed with the U.S. Securities and Exchange Commission (the "SEC"). The condensed consolidating financial statements present investments in both consolidated and unconsolidated affiliates using the equity method of accounting.

The following condensed consolidating financial information presents: balance sheets as of June 30, 2011 and December 31, 2010, statements of operations for each of the three and six months ended June 30, 2011 and 2010 and the statements of cash flows for each of the six months ended June 30, 2011 and 2010 of (a) Core Laboratories N.V., parent/guarantor, (b) Core Laboratories LP, issuer of public debt securities guaranteed by Core Laboratories N.V., (c) the non-guarantor subsidiaries, (d) consolidating adjustments

12

necessary to consolidate Core Laboratories N.V. and its subsidiaries and (e) Core Laboratories N.V. on a consolidated basis.

13

Condensed Consolidating Balance Sheets (Unaudited)
(In thousands)	June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	9,240	$	6,138	$	9,183	$	—		$	24,561
Accounts receivable, net	281		35,209		124,718		—			160,208
Inventories, net	—		4,264		38,244		—			42,508
Prepaid expenses and other current assets	6,122		8,632		12,660		—			27,414
Total current assets	15,643		54,243		184,805		—			254,691
PROPERTY, PLANT AND EQUIPMENT, net	—		20,921		84,205		—			105,126
GOODWILL AND INTANGIBLES, net	46,986		15,445		99,988		—			162,419
INTERCOMPANY RECEIVABLES	18,720		89,185		397,713		(505,618		)	—
INVESTMENT IN AFFILIATES	566,537		—		1,596,076		(2,161,801		)	812
DEFERRED TAX ASSET	2,453		—		5,978		(1,629		)	6,802
OTHER ASSETS	3,347		15,713		3,323		—			22,383
TOTAL ASSETS	$	653,686	$	195,507	$	2,372,088	$	(2,669,048	)	$	552,233
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	8,968	$	8,974	$	43,389	$	—		$	61,331
Short-term debt	—		89,747		—		—			89,747
Other accrued expenses	2,366		30,844		51,810		—			85,020
Total current liabilities	11,334		129,565		95,199		—			236,098
LONG-TERM DEBT	—		—		—		—			—
DEFERRED COMPENSATION	6,476		17,421		104		—			24,001
DEFERRED TAX LIABILITY	—		762		867		(1,629		)	—
INTERCOMPANY PAYABLES	372,606		—		133,012		(505,618		)	—
OTHER LONG-TERM LIABILITIES	14,207		2,963		20,579		—			37,749
Equity Component of Short-term Debt -Senior Exchangeable Notes	—		2,183		—		—			2,183
SHAREHOLDERS' EQUITY	249,063		42,613		2,119,188		(2,161,801		)	249,063
NON-CONTROLLING INTEREST	—		—		3,139		—			3,139
TOTAL EQUITY	249,063		42,613		2,122,327		(2,161,801		)	252,202
TOTAL LIABILITIES AND EQUITY	$	653,686	$	195,507	$	2,372,088	$	(2,669,048	)	$	552,233

14

Condensed Consolidating Balance Sheets
(In thousands)	December 31, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	11,162	$	88,612	$	34,106	$	—		$	133,880
Accounts receivable, net	10		33,637		121,079		—			154,726
Inventories, net	—		4,127		29,852		—			33,979
Prepaid expenses and other current assets	5,641		9,437		11,657		—			26,735
	16,813		135,813		196,694		—			349,320
PROPERTY, PLANT AND EQUIPMENT, net	—		21,139		83,084		—			104,223
GOODWILL AND INTANGIBLES, net	46,986		15,838		100,053		—			162,877
INTERCOMPANY RECEIVABLES	21,749		164,945		242,754		(429,448		)	—
INVESTMENT IN AFFILIATES	553,693		—		1,567,416		(2,120,414		)	695
DEFERRED TAX ASSET	2,810		—		6,436		(9,246		)	—
OTHER ASSETS	3,209		13,099		2,619		—			18,927
TOTAL ASSETS	$	645,260	$	350,834	$	2,199,056	$	(2,559,108	)	$	636,042
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	336	$	5,144	$	39,230	$	—		$	44,710
Short-term debt	—		147,543		—		—			147,543
Other accrued expenses	2,291		29,250		55,559		—			87,100
	2,627		181,937		94,789		—			279,353
DEFERRED COMPENSATION	6,159		14,981		101		—			21,241
DEFERRED TAX LIABILITY	—		11,444		—		(9,246		)	2,198
INTERCOMPANY PAYABLES	333,651		—		95,797		(429,448		)	—
OTHER LONG-TERM LIABILITIES	13,332		1,099		17,615		—			32,046
Equity Component of Short-term Debt -Senior Exchangeable Notes	—		8,864		—		—			8,864
SHAREHOLDERS' EQUITY	289,491		132,509		1,987,905		(2,120,414		)	289,491
NON-CONTROLLING INTEREST	—		—		2,849		—			2,849
TOTAL EQUITY	289,491		132,509		1,990,754		(2,120,414		)	292,340
TOTAL LIABILITIES AND EQUITY	$	645,260	$	350,834	$	2,199,056	$	(2,559,108	)	$	636,042

15

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	52,935		$	172,850		$	—		$	225,785
Intercompany revenue	409		6,314			30,838			(37,561		)	—
Earnings (loss) from consolidated affiliates	48,014		—			90,507			(138,521		)	—
Total revenue	48,423		59,249			294,195			(176,082		)	225,785
OPERATING EXPENSES
Operating costs	264		26,698			125,311			—			152,273
General and administrative expenses	1,971		7,784			2			—			9,757
Depreciation and amortization	—		1,599			4,206			—			5,805
Other (income) expense, net	814		3,664			29,915			(34,246		)	147
Operating income	45,374		19,504			134,761			(141,836		)	57,803
Loss on exchange of Senior Exchangeable Notes	—		210			—			—			210
Interest expense	—		24,256			—			(21,757		)	2,499
Income (loss) before income tax expense	45,374		(4,962		)	134,761			(120,079		)	55,094
Income tax expense (benefit)	4,923		(8,436		)	18,223			—			14,710
Net income	40,451		3,474			116,538			(120,079		)	40,384
Net income (loss) attributable to non-controlling interest	—		—			(67		)	—			(67		)
Net income (loss) attributable to Core Laboratories	$	40,451	$	3,474		$	116,605		$	(120,079	)	$	40,451

16

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Six Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—		$	100,735		$	331,783		$	—		$	432,518
Intercompany revenue	769			11,695			70,894			(83,358		)	—
Earnings (loss) from consolidated affiliates	86,708			—			70,803			(157,511		)	—
Total revenue	87,477			112,430			473,480			(240,869		)	432,518
OPERATING EXPENSES
Operating costs	558			51,997			236,468			—			289,023
General and administrative expenses	4,615			14,654			12			—			19,281
Depreciation and amortization	—			3,229			8,407			—			11,636
Other (income) expense, net	943			6,609			56,342			(65,618		)	(1,724		)
Operating income	81,361			35,941			172,251			(175,251		)	114,302
Loss on exchange of Senior Exchangeable Notes	—			839			—			—			839
Interest expense	—			83,009			—			(78,150		)	4,859
Income (loss) before income tax expense	81,361			(47,907		)	172,251			(97,101		)	108,604
Income tax expense (benefit)	(5,380		)	10,991			16,617			—			22,228
Net income	86,741			(58,898		)	155,634			(97,101		)	86,376
Net income (loss) attributable to non-controlling interest	—			—			(365		)	—			(365		)
Net income (loss) attributable to Core Laboratories	$	86,741		$	(58,898	)	$	155,999		$	(97,101	)	$	86,741

17

Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Six Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by (used in) operating activities	$	128,131		$	(14,422	)	$	(15,755	)	$	—	$	97,954
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—			(1,256		)	(10,728		)	—		(11,984		)
Patents and other intangibles	—			(16		)	(116		)	—		(132		)
Proceeds from sale of assets	—			34			137			—		171
Proceeds from insurance recovery	—			—			884			—		884
Premiums on life insurance	—			(1,243		)	—			—		(1,243		)
Net cash used in investing activities	—			(2,481		)	(9,823		)	—		(12,304		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt borrowings	—			(64,477		)	—			—		(64,477		)
Stock options exercised	241			—			—			—		241
Excess tax benefits from stock-based compensation	2,289			—			—			—		2,289
Debt financing costs	—			(1,094		)	—			—		(1,094		)
Settlement of Warrants	(57,777		)	—			—			—		(57,777		)
Non-controlling interest - contributions	—			—			895			—		895
Non-controlling interest - dividends	—			—			(240		)	—		(240		)
Dividends paid	(22,709		)	—			—			—		(22,709		)
Repurchase of common shares	(52,097		)	—			—			—		(52,097		)
Net cash provided by (used in) financing activities	(130,053		)	(65,571		)	655			—		(194,969		)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(1,922		)	(82,474		)	(24,923		)	—		(109,319		)
CASH AND CASH EQUIVALENTS, beginning of period	11,162			88,612			34,106			—		133,880
CASH AND CASH EQUIVALENTS, end of period	$	9,240		$	6,138		$	9,183		$	—	$	24,561

18

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	48,386	$	150,516	$	—		$	198,902
Intercompany revenue	379		7,619		35,451		(43,449		)	—
Earnings from consolidated affiliates	37,709		—		115,745		(153,454		)	—
Total revenue	38,088		56,005		301,712		(196,903		)	198,902
OPERATING EXPENSES
Operating costs	322		25,237		103,358		—			128,917
General and administrative expenses	2,147		7,060		4		—			9,211
Depreciation and amortization	—		1,554		4,212		—			5,766
Other (income) expense, net	992		3,411		29,884		(32,999		)	1,288
Operating income	34,627		18,743		164,254		(163,904		)	53,720
Loss on exchange of Senior Exchangeable Notes	—		—		—		—			—
Interest expense	—		4,112		2		—			4,114
Income before income tax expense	34,627		14,631		164,252		(163,904		)	49,606
Income tax expense (benefit)	411		5,992		8,841		—			15,244
Net income	34,216		8,639		155,411		(163,904		)	34,362
Net income attributable to non-controlling interest	—		—		146		—			146
Net income attributable to Core Laboratories	$	34,216	$	8,639	$	155,265	$	(163,904	)	$	34,216

19

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Six Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	93,547	$	293,692	$	—		$	387,239
Intercompany revenue	667		12,206		70,960		(83,833		)	—
Earnings from consolidated affiliates	72,898		—		216,504		(289,402		)	—
Total revenue	73,565		105,753		581,156		(373,235		)	387,239
OPERATING EXPENSES
Operating costs	712		50,221		203,572		—			254,505
General and administrative expenses	4,314		11,270		7		—			15,591
Depreciation and amortization	—		3,112		8,408		—			11,520
Other (income) expense, net	857		5,002		58,192		(63,561		)	490
Operating income	67,682		36,148		310,977		(309,674		)	105,133
Interest expense	—		8,167		6		—			8,173
Income before income tax expense	67,682		27,981		310,971		(309,674		)	96,960
Income tax expense (benefit)	1,261		11,474		17,577		—			30,312
Net income	66,421		16,507		293,394		(309,674		)	66,648
Net income attributable to non-controlling interest	—		—		227		—			227
Net income attributable to Core Laboratories	$	66,421	$	16,507	$	293,167	$	(309,674	)	$	66,421

20

Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Six Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by operating activities	$	54,349		$	44,964		$	12,047		$	—	$	111,360
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—			(2,918		)	(9,778		)	—		(12,696		)
Patents and other intangibles	—			—			(142		)	—		(142		)
Acquisitions, net of cash	—			(9,000		)	—			—		(9,000		)
Proceeds from sale of assets	—			11			114			—		125
Premiums on life insurance	—			(921		)	—			—		(921		)
Net cash used in investing activities	—			(12,828		)	(9,806		)	—		(22,634		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock options exercised	295			—			—			—		295
Excess tax benefit from stock-based payments	798			—			—			—		798
Non-controlling interest - dividends	—			—			(181		)	—		(181		)
Dividends paid	(5,375		)	—			—			—		(5,375		)
Repurchase of common shares	(91,686		)	—			—			—		(91,686		)
Net cash used in financing activities	(95,968		)	—			(181		)	—		(96,149		)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(41,619		)	32,136			2,060			—		(7,423		)
CASH AND CASH EQUIVALENTS, beginning of period	73,998			95,048			11,999			—		181,045
CASH AND CASH EQUIVALENTS, end of period	$	32,379		$	127,184		$	14,059		$	—	$	173,622

13. RECENT ACCOUNTING PRONOUNCEMENTS

In May 2011, the FASB issued ASU 2011-04) which relates to fair value measurement (FASB ASC Topic 820), which amends current guidance to achieve common fair value measurement and disclosure requirements in U.S. GAAP and International Financial Reporting Standards. The amendments generally represent clarification of FASB ASC Topic 820, but also include instances where a particular principle or requirement for measuring fair value or disclosing information about fair value measurements has changed. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. We will adopt this pronouncement for our fiscal year beginning January 1, 2012. We do not expect this pronouncement to have a material effect on our consolidated financial statements.

In June 2011, the FASB issued ASU 2011-05which provides new guidance on the presentation of comprehensive income (FASB ASC Topic 220) in financial statements. Entities are required to present total comprehensive income either in a single, continuous statement of comprehensive income or in two separate, but consecutive, statements. Under the single-statement approach, entities must include the components of net income, a total for net income, the components of other comprehensive income and a total for comprehensive income. Under the two-statement approach, entities must report an income statement and, immediately following, a statement of other comprehensive income. Under either method, entities must display adjustments for items reclassified from other comprehensive income to net income in both net income and other comprehensive income. The provisions for this pronouncement are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with early adoption permitted. We will adopt this pronouncement for our fiscal year beginning January 1, 2012.

21

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion summarizes the financial position of Core Laboratories N.V. and its subsidiaries as of June 30, 2011 and should be read in conjunction with (i) the unaudited consolidated interim financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q and (ii) the consolidated financial statements and accompanying notes to our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

General

Core Laboratories N.V. is a Netherlands limited liability company.  It was established in 1936 and is one of the world's leading providers of proprietary and patented reservoir description, production enhancement and reservoir management products and services to the oil and gas industry.  These products and services can enable our clients to improve reservoir performance and increase oil and gas recovery from their producing fields.  Core Laboratories N.V. has over 70 offices in more than 50 countries and employs approximately 5,000 people worldwide.

References to "Core Lab", "we", "our" and similar phrases are used throughout this Quarterly Report on Form 10-Q and relate collectively to Core Laboratories N.V. and its consolidated affiliates.

Our business units have been aggregated into three complementary segments, which provide products and services for improving reservoir performance and increasing oil and gas recovery from new and existing fields.

• Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.

• Production Enhancement: Includes products and services relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.

• Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Certain statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations section, including those under the headings "Outlook" and "Liquidity and Capital Resources", and in other parts of this Form 10-Q, are forward-looking. In addition, from time to time, we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. Forward-looking statements can be identified by the use of forward-looking terminology such as "may", "will", "believe", "expect", "anticipate", "estimate", "continue", or other similar words, including statements as to the intent, belief, or current expectations of our directors, officers, and management with respect to our future operations, performance, or positions or which contain other forward-looking information. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. While management believes that these forward-looking statements are reasonable as and when made, no assurances can be given that the future results indicated, whether expressed or implied, will be achieved. While we believe that these statements are and will be accurate, our actual results and experience may differ materially from the anticipated results or other expectations expressed in our statements due to a variety of risks and uncertainties.

The oil and gas industry is highly cyclical and demand for the majority of our oilfield products and services is substantially dependent on the level of expenditures by the oil and gas industry for the exploration, development and production of crude oil and natural gas reserves, which are sensitive to oil and natural gas prices and generally dependent on the industry's view of future oil and gas prices. There are numerous factors affecting the supply of and demand for our products and services, which are summarized as:

•general and economic business conditions;

•market prices of oil and gas and expectations about future prices;

22

•cost of producing oil and natural gas;

•the level of drilling and production activity;

•mergers, consolidations and downsizing among our clients;

•coordination by OPEC;

•the impact of commodity prices on the expenditure levels of our clients;

•financial condition of our client base and their ability to fund capital expenditures;

•the physical effects of climatic change, including adverse weather or geologic/geophysical conditions;

• the adoption of legal requirements or taxation relating to climate change that lower the demand for petroleum-based fuels;

•civil unrest or political uncertainty in oil producing or consuming countries;

•level of consumption of oil, gas and petrochemicals by consumers;

•changes in existing laws, regulations, or other governmental actions;

•the business opportunities (or lack thereof) that may be presented to and pursued by us;

•availability of services and materials for our clients to grow their capital expenditures; and

•availability of materials and equipment from key suppliers.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in the forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed discussion of some of the foregoing risks and uncertainties, see "Item 1A - Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as well as the other reports filed by us with the Securities and Exchange Commission (“SEC”).

Outlook

We continue our efforts to expand our market presence by opening or expanding facilities in strategic areas and realizing synergies within our business lines.  We believe our market presence provides us a unique opportunity to service clients who have global operations in addition to the national oil companies.

We have established internal earnings targets that are based on market conditions existing at the time our targets were established.  Based on recent activity levels, we believe that the current level of activities, workflows, and operating margins both outside North America and within North America will grow moderately during the remainder of 2011. Because of high demand and a fire at a raw materials supplier, shortages of some high performance specialty steel tubulars used with the Company's perforating systems may occur in the third quarter of 2011. The Company has added additional suppliers but lead times required for the specialty steel production could delay receipt of the supplies needed to meet third quarter demand. Therefore, third quarter 2011 revenue and operating income for our Production Enhancement operations may be negatively affected.

Results of Operations

Our results of operations as a percentage of applicable revenue were as follows (in thousands):

23

(Unaudited)	Three Months Ended June 30,									% Change
	2011					2010				2011/2010
REVENUE:
Services	$	169,756		75	%	$	153,010	77	%	11	%
Product sales	56,029			25	%	45,892		23	%	22	%
Total revenue	225,785			100	%	198,902		100	%	14	%
OPERATING EXPENSES:
Cost of services*	112,001			66	%	96,411		63	%	16	%
Cost of product sales*	40,272			72	%	32,506		71	%	24	%
Total cost of services and product sales	152,273			67	%	128,917		65	%	18	%
General and administrative expenses	9,757			4	%	9,211		5	%	6	%
Depreciation and amortization	5,805			3	%	5,766		3	%	1	%
Other (income), net	147			—	%	1,288		1	%	(89	)%
Operating income	57,803			26	%	53,720		27	%	8	%
Loss on exchange of Senior Exchangeable Notes	210			—	%	—		—	%	—	%
Interest expense	2,499			1	%	4,114		2	%	(39	)%
Income before income tax expense	55,094			24	%	49,606		25	%	11	%
Income tax expense	14,710			7	%	15,244		8	%	(4	)%
Net income	40,384			18	%	34,362		17	%	18	%
Net income (loss) attributable to non-controlling interest	(67		)	—	%	146		—	%	(146	)%
Net income attributable to Core Laboratories N.V.	$	40,451		18	%	$	34,216	17	%	18	%
* Percentage based on applicable revenue rather than total revenue

(Unaudited)	Six Months Ended June 30,								% Change
	2011				2010				2011/2010
REVENUE:
Services	322,870		75	%	$	296,452	77	%	9	%
Product sales	109,648		25	%	90,787		23	%	21	%
Total revenue	432,518		100	%	387,239		100	%	12	%
OPERATING EXPENSES:
Cost of services*	212,733		66	%	191,768		65	%	11	%
Cost of product sales*	76,290		70	%	62,737		69	%	22	%
Total cost of services and product sales	289,023		67	%	254,505		66	%	14	%
General and administrative expenses	19,281		4	%	15,591		4	%	24	%
Depreciation and amortization	11,636		3	%	11,520		3	%	1	%
Other (income), net	(1,724	)	—	%	490		—	%	(452	)%
Operating income	114,302		26	%	105,133		27	%	9	%
Loss on exchange of Senior Exchangeable Notes	839		—	%	—		—	%	—	%
Interest expense	4,859		1	%	8,173		2	%	(41	)%
Income before income tax expense	108,604		25	%	96,960		25	%	12	%
Income tax expense	22,228		5	%	30,312		8	%	(27	)%
Net income	86,376		20	%	66,648		17	%	30	%
Net income (loss) attributable to non-controlling interest	(365	)	—	%	227		—	%	(261	)%
Net income attributable to Core Laboratories N.V.	86,741		20	%	$	66,421	17	%	31	%
* Percentage based on applicable revenue rather than total revenue

24

Operating Results for the Three and Six Months EndedJune 30, 2011 Compared to the Three and Six Months EndedJune 30, 2010 (unaudited)

Service Revenue

Service revenue increased to $169.8 million for the second quarter of 2011, up 11% when compared to $153.0 million for the second quarter of 2010.  For the six months endedJune 30, 2011, service revenue increased 9% to $322.9 million compared to $296.5 million for the respective period in 2010. The increase in service revenue was due to the increases in reservoir rock and reservoir fluids phase-behavior studies of 14% and 12% and in crude oil testing, inspection, distillation, assay, fractionation and characterization projects worldwide of 16% and 10% for the comparable three and six months endedJune 30, 2011 and 2010, respectively.  Our large scale core analyses and reservoir fluid projects combined with our fluid and derived products inspection, calibration and assay work continue to provide meaningful revenue streams in the Middle East, Asia-Pacific and off the coasts of Africa showing increases of 19%, 21% and 13%, respectively, for the second quarter 2011 compared to the same period in 2010, and 13%, 21% and 7%, respectively, for the six months endedJune 30, 2011 compared to 2010.  

Product Sales Revenue

Revenue associated with product sales increased to $56.0 million for the second quarter of 2011, up 22% from $45.9 million for the second quarter of 2010. For the six months endedJune 30, 2011, product sale revenues increased 21% to $109.6 million compared to $90.8 million for the same period in 2010. The increase in revenue was driven by the acceptance of and demand for our specialized completion products in North American natural gas and oil shale reservoirs demonstrated by an increase of 34% and 27% for the comparable three and six months ended June 30, 2011 and 2010, respectively.   These specialized optimizing technologies are focused on high-end well completion and stimulation programs mainly in the Haynesville, Marcellus, Montney and Eagle Ford shale plays and in multi-stage completions in the Bakken, Niobrara and Eagle Ford oil-shale plays. We are also providing completion and recompletion technologies and services to be used in reworking major, giant, and super-giant fields in southern Iraq.

Cost of Services

Cost of services expressed as a percentage of service revenue was 66% for the quarter ended June 30, 2011, up from 63% in the same period in 2010 due to a charge taken during the second quarter of 2011 for one-time severance and other personnel costs. For the six months endedJune 30, 2011, cost of services expressed as a percentage of service revenue was 66% as compared to 65% for the same period in 2010.

Cost of Product Sales

Cost of sales expressed as a percentage of product sales revenue was 72% for the quarter ended June 30, 2011, up slightly from 71% during the same period in 2010. For the six months endedJune 30, 2011, cost of product sales expressed as a percentage of sales revenue was 70%, up from 69% for the same period in 2010.

General and Administrative Expenses

General and administrative expenses totaled $9.8 million for the second quarter of 2011, up from the $9.2 million incurred in the second quarter of 2010. The increase in general and administrative expenses was primarily due to charges incurred for compensation related expenses. For the six months endedJune 30, 2011, general and administrative expenses were 4% of revenue at $19.3 million compared to $15.6 million, also 4% of revenue, for the same period in 2010.

Depreciation and Amortization Expense

Depreciation and amortization expense was $5.8 million for the second quarter of 2011, unchanged from the second quarter of 2010. For the six months endedJune 30, 2011, depreciation and amortization expense was $11.6 million, an increase of $0.1 million from the six months endedJune 30, 2010.

Other (Income) Expense, Net

Other (income) expense, net consisted of the following for the quarter and six months endedJune 30, 2011 and 2010 (in thousands):

25

	Three Months Ended June 30,						Six Months Ended June 30,
	2011			2010			2011			2010
	(Unaudited)						(Unaudited)
(Gain) loss on sale of assets	$	(75	)	$	39		$	(138	)	$	8
Foreign exchange (gain) loss	(9		)	1,712			(521		)	1,621
Interest income	(30		)	(130		)	(85		)	(142		)
Rents and royalties	(382		)	(218		)	(833		)	(700		)
Gain on insurance recovery	(69		)	—			(779		)	—
Legal entity realignment	711			—			711			—
Other, net	1			(115		)	(79		)	(297		)
Total other (income) expense, net	$	147		$	1,288		$	(1,724	)	$	490

During the third quarter of 2010, an office and laboratory facility was damaged by fire, resulting in the loss of the laboratory portion of the building, as well as some of the laboratory equipment.  The final settlement was reached in the first quarter of 2011, which resulted in a gain of $0.8 million.

Foreign exchange (gains) losses by currency are summarized in the following table (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	June 30, 2011		June 30, 2010		June 30, 2011		June 30, 2010
	(Unaudited)				(Unaudited)
British Pound	44		158		(47	)	416
Canadian Dollar	(124	)	149		(543	)	(236	)
Euro	41		1,619		(25	)	1,589
Mexican Peso	36		(14	)	142		94
Russian Ruble	(24	)	(69	)	(219	)	(15	)
Other currencies, net	18		(131	)	171		(227	)
Total (gain) loss	(9	)	1,712		(521	)	1,621

Loss on Exchange of Senior Exchangeable Notes

Under the terms of the Notes, defined criteria were met which allowed the Notes to be early exchanged during the second quarter of 2011, as it was during the first quarter of 2011, and as a result the equity component of the Notes at June 30, 2011 was classified as temporary equity.  This balance combined with the debt amount reflects the amount that could result in cash settlement upon exchange.  We received nine requests to exchange 17,909 Notes which were settled during the second quarter of 2011 for $17.9 million in cash and 213,936 shares of our common stock, all of which were treasury shares, resulting in a loss of $0.2 million.  We also received five requests during the second quarter of 2011 to exchange 888 Notes which we will settle during the third quarter upon completion of the requisite holding period per the Note Indenture agreement.

Interest Expense

Interest expense for the three months ended June 30, 2011 and 2010 was $2.5 million and $4.1 million, respectively, which included $1.8 million and $3.9 million, respectively, of non-cash interest expense due to the amortization of the discount on the Notes.  Interest expense for the six months endedJune 30, 2011 and 2010 was $4.9 million and $8.2 million, respectively, which included $4.0 million and $7.7 million, respectively, of non-cash interest expense due to the amortization of the discount on the Notes.  As 146,728 of our $1,000 principal amount Notes were exchanged between June 30, 2010 and June 30, 2011, the associated discount was moved to equity resulting in a lower amount of amortization to interest expense.

Income Tax Expense

The effective tax rates for the three months ended June 30, 2011 and 2010 were 26.7% and 30.7%, respectively, due to a mix of earnings in various tax jurisdictions.  The effective tax rates for year to date 2011 and 2010 were 20.5% and 31.3%, respectively. Included in income tax expense is the reversal in the six months ended June 30, 2011 of $10.4 million in tax liabilities provided over the period 2007-2010 as a result of recently concluded audits of prior year returns.  The liability

26

reversal reflects the impact of positions sustained in certain audits.

Segment Analysis

Our operations are managed primarily in three complementary segments - Reservoir Description, Production Enhancement and Reservoir Management.  The following tables summarize our results by operating segment for the three and six months ended June 30, 2011 and 2010 (in thousands):

	Three Months Ended June 30,						% Change
	2011			2010			2011/2010
Revenues:	(Unaudited)
Reservoir Description	$	118,758		$	106,528		11	%
Production Enhancement	88,787			79,717			11	%
Reservoir Management	18,240			12,657			44	%
Consolidated	$	225,785		$	198,902		14	%
Operating income (loss):
Reservoir Description	$	26,629		$	25,074		6	%
Production Enhancement	24,500			26,152			(6	)%
Reservoir Management	7,307			3,672			99	%
Corporate and Other1	(633		)	(1,178		)	NM
Consolidated	$	57,803		$	53,720		8	%
(1) "Corporate and Other" represents those items that are not directly related to a particular segment
"NM"  means not meaningful

	Six Months Ended June 30,						% Change
	2011			2010			2011/2010
Revenues:	(Unaudited)
Reservoir Description	$	226,379		$	210,621		7	%
Production Enhancement	170,885			148,561			15	%
Reservoir Management	35,254			28,057			26	%
Consolidated	$	432,518		$	387,239		12	%
Operating income (loss):
Reservoir Description	$	53,067		$	50,215		6	%
Production Enhancement	47,762			47,095			1	%
Reservoir Management	13,971			9,292			50	%
Corporate and Other1	(498		)	(1,469		)	NM
Consolidated	$	114,302		$	105,133		9	%
(1) "Corporate and Other" represents those items that are not directly related to a particular segment
"NM"  means not meaningful

Reservoir Description

Revenue from the Reservoir Description segment increased 11%, or $12.2 million, to $118.8 million in the second quarter of 2011, compared to $106.5 million in the second quarter of 2010.  For the six months endedJune 30, 2011, revenues increased 7%, or $15.8 million, to $226.4 million from $210.6 million for the six months endedJune 30, 2010. This segment’s operations, which are more focused on international crude-oil related products, continue to focus on large-scale core analyses and reservoir fluids characterization studies from Asia-Pacific areas, offshore West and East Africa, the Eastern Mediterranean region and the Middle East, including Iraq, Kuwait, and the United Arab Emirates.  This segment continued to realize increased

27

demand of 12% for reservoir fluids phase-behavior studies, and of 6% for crude oil testing, inspection, distillation, assay, fractionation and characterization projects worldwide.

Operating income in the second quarter of 2011 increased by 6%, or $1.6 million, to $26.6 million compared to $25.1 million for the second quarter of 2010.  Operating income for the six months endedJune 30, 2011 increased by 6%, or $2.9 million, to $53.1 million. Operating margin for the quarter ended June 30, 2011 was 22%, compared to 24% for the same period in 2010 due to a charge taken during the second quarter of 2011 for one-time severance and other personnel costs. This segment emphasizes technologically demanding services on internationally-based development and production-related crude oil projects over the more cyclical exploration-related projects.

Production Enhancement

Revenue from the Production Enhancement segment increased by 11%, or $9.1 million, to $88.8 million in the second quarter of 2011 compared to $79.7 million in the second quarter of 2010. Revenues increased by 15%, or $22.3 million, to $170.9 million for the six months endedJune 30, 2011 compared to $148.6 million for the same period in 2010. The revenue increase was due to increased sales of our completion products and gun systems particularly in markets relating to horizontal well developments of gas-shale and oil-shale reservoirs of 33% and 30% for the three and six months ended June 30, 2011, respectively, when compared to the same periods in 2010 . The average number of horizontal rigs operating per month in North America, as reported by Baker Hughes Incorporated, increased to 1,040 during the second quarter of 2011 from 780 in the second quarter of 2010 and increased to 1,000 for the six months ended June 30, 2011 from 720 during the same period in 2010. Demand for our Horizontal Time-Delayed Ballistics Actuated Sequential Transfer (HTD-Blast™) technology in the Eagle Ford, Niobrara, and Granite Wash formations and for horizontal unconventional crude-oil plays in West Texas increased 51% and 91% for the three and six months ended June 30, 2011, respectively, over the same periods in 2010. In addition, we have increased our investment in inventory by 25% during the six months endedJune 30, 2011. Because of high demand and a fire at a raw materials supplier, additional suppliers for high performance specialty steel tubulars have been added for delivery in the third quarter of 2011.

Operating income in the second quarter of 2011 decreased by 6%, or $1.7 million, to $24.5 million from $26.2 million for the second quarter of 2010.  Operating margins decreased to 28% in the second quarter of 2011 compared to 33% for the same period in 2010.   Operating margins were adversely affected during the second quarter of 2011 by a number of transitory issues including weather-related project delays in the Bakken shale region and delays of specific international field-flood diagnostic projects. For the six months endedJune 30, 2011, operating income increased to $47.8 million, an increase of 1% over the same period in 2010. The increase in operating income from 2010 to 2011 was primarily driven by increased revenue from services related to our proprietary and patented diagnostic technologies, such as SpectraChem^® Plus+, SpectraScan^®, ZeroWash^®, our HERO™ line of perforating charges and gun systems and our HTD-Blast™ perforating system which is used for the perforation of extended-reach horizontal completions.  

Reservoir Management

Revenue from the Reservoir Management segment increased by 44%, to $18.2 million, in the second quarter of 2011 compared to $12.7 million for the second quarter of 2010.  Revenues for the six months endedJune 30, 2011 were $35.3 million, an increase of 26% from $28.1 million for the same period in 2010. The increase in revenue was due to ongoing interest in several of our existing multi-client reservoir studies as revenues from the North American Gas Shale Study increased 74%, the Marcellus Shale Evaluation study increased 66% and the Haynesville & Bossier Shale Evaluation study increased 43% during the second quarter of 2011 compared to the second quarter of 2010. Revenues from the North American Shale Study increased 71% for the six month period ended June 30, 2011 compared to the same period in 2010.

Operating income in the second quarter of 2011 increased 99% to $7.3 million from $3.7 million for the second quarter of 2010. For the six months endedJune 30, 2011, operating income was $14.0 million, compared to $9.3 million for the same period in 2010. Operating margins increased to 40% in the second quarter of 2011 compared to 29% for the same period in 2010. The increase in operating income was related to growth in our consortium projects and the delivery of completed consortium projects. During the six months ended June 30, 2011, the total number of participants for all studies increased by 77 members from the same date in 2010, a 32% increase, including a 67% increase in the number of participants in our Global Shale study, a 31% increase in our Eagle Ford Shale study and a 17% increase in our Marcellus Shale study. In addition, we have added 44 participants into four new studies which began after June 30, 2010

Liquidity and Capital Resources

General

28

We have historically financed our activities through cash on hand, cash flows from operations, bank credit facilities, or the issuance of debt and equity financing.

We utilize the non-GAAP financial measure of free cash flow to evaluate our cash flows and results of operations.  Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less capital expenditures.  Management believes that free cash flow provides useful information to investors regarding the cash that was available in the period that was in excess of our needs to fund our capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP, and should not be considered in isolation nor construed as an alternative to operating profit, net income (loss) or cash flows from operating, investing or financing activities, each as determined in accordance with GAAP. Free cash flow does not represent residual cash available for distribution because we may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented, may not be comparable to similarly titled measures presented by other companies.  The following table reconciles this non-GAAP financial measure to the most directly comparable measure calculated and presented in accordance with GAAP for the six months ended June 30, 2011 and 2010 (in thousands):

	Six Months Ended June 30,				% Change
	2011		2010		2011/2010
Free cash flow calculation:	(Unaudited)
Net cash provided by operating activities	$	97,954	$	111,360	(12	)%
Less:  capital expenditures	11,984		12,696		(6	)%
Free cash flow	$	85,970	$	98,664	(13	)%

The decrease in free cash flow in 2011 compared to 2010 was primarily attributable to an increase in inventory in order to stock three new warehouses which were opened in 2011 and a utilization of income tax receivables in 2010. This was partially offset by an increase in net income and a decrease in capital expenditures.

Cash Flows

The following table summarizes cash flows for the six months ended June 30, 2011 and 2010 (in thousands):

	Six Months Ended June 30,						% Change
	2011			2010			2011/2010
Cash provided by/(used in):	(Unaudited)
Operating activities	$	97,954		$	111,360		(12	)%
Investing activities	(12,304		)	(22,634		)	(46	)%
Financing activities	(194,969		)	(96,149		)	103	%
Net change in cash and cash equivalents	$	(109,319	)	$	(7,423	)	1,373	%

The decrease in cash flows provided by operating activities was the result of an increase in inventory in order to stock three new warehouses which were opened in 2011 and a utilization of income tax receivables in 2010.

Cash flows used in investing activities were higher during the six months ended June 30, 2010 primarily due to an acquisition for $9.0 million.

The increase in cash flows used in financing activities was caused by three types of transactions: the early exchange of our Notes, early settlement of our outstanding warrants and an increase in cash dividends. 

We received nine requests to exchange 17,909 of our $1,000 face value Notes which were settled during the second quarter of 2011 for $17.9 million in cash and 213,936 treasury shares. During the second quarter of 2011, we accelerated the settlement of approximately 25% of our outstanding warrants resulting in a cash payment of $57.8 million. In the first quarter of 2011, our Board of Directors announced an increase of our quarterly dividend resulting in an increase of $17.3 million in

29

dividends paid during the first six months of 2011 over the same period of 2010.  

The increased uses of cash described above were partially offset by a decrease in the number of shares repurchased under our common share repurchase program.  In the first six months of 2011, we repurchased 574,174 shares for an aggregate price of $52.1 million compared to 1,483,280 shares for an aggregate price of $91.7 million during the same period in 2010.

Credit Facilities and Available Future Liquidity

In 2006, Core Laboratories LP, an entity 100% indirectly owned by Core Laboratories N.V., issued $300 million aggregate principal amount of Senior Exchangeable Notes which are fully and unconditionally guaranteed by Core Laboratories N.V. and mature on October 31, 2011.

Under the terms of the Notes, defined criteria was met which allowed the Notes to be early exchanged during the second quarter of 2011, as it was during the first quarter of 2011, and as a result the equity component of the Notes at June 30, 2011 was classified as temporary equity.  This balance combined with the debt amount reflects the amount that could result in cash settlement upon exchange.  We received nine requests to exchange 17,909 Notes during the first and second quarters of 2011 which were settled for $17.9 million in cash and 213,936 shares of our common stock, all of which were treasury shares, resulting in a loss of $0.2 million.  We also received five requests during the second quarter to exchange 888 Notes which we will settle during the third quarter upon completion of the requisite holding period per the Note Indenture agreement.

We maintain a revolving credit facility (the "Credit Facility") that allowed for an aggregate borrowing capacity of $300.0 million at June 30, 2011. The Credit Facility also provided an option to increase the commitment under the Credit Facility to $350 million, if certain conditions are met.  The Credit Facility bears interest at variable rates from LIBOR plus 1.75% to a maximum of LIBOR plus 2.50%.  Any outstanding balance under the Credit Facility is due in December 2015 when the Credit Facility matures.   Interest payment terms are variable depending upon the specific type of borrowing under this facility. Our available capacity is reduced by outstanding letters of credit and performance guarantees and bonds totaling $14.5 million at June 30, 2011 relating to certain projects in progress.  Our available borrowing capacity under the Credit Facility at June 30, 2011 was $285.5 million.  As of June 30, 2011, we had $17.9 million of outstanding letters of credit and performance guarantees and bonds in addition to those under the Credit Facility.

The terms of the Credit Facility require us to meet certain financial and operational covenants. We believe that we were in compliance with all such covenants at June 30, 2011.  All of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility.

Our ability to maintain and grow our operating income and cash flow depends, to a large extent, on continued investing activities. We are a Netherlands holding company and substantially all of our operations are conducted through subsidiaries. Consequently, our cash flow depends upon the ability of our subsidiaries to pay cash dividends or otherwise distribute or advance funds to us.  We believe our future cash flows from operations, supplemented by our borrowing capacity and issuances of additional equity, should be sufficient to fund our debt requirements, capital expenditures, working capital, dividend payments and future acquisitions.

Recent Accounting Pronouncements

In May 2011, the FASB issued ASU 2011-04) which relates to fair value measurement (FASB ASC Topic 820), which amends current guidance to achieve common fair value measurement and disclosure requirements in U.S. GAAP and International Financial Reporting Standards. The amendments generally represent clarification of FASB ASC Topic 820, but also include instances where a particular principle or requirement for measuring fair value or disclosing information about fair value measurements has changed. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. We will adopt this pronouncement for our fiscal year beginning January 1, 2012. We do not expect this pronouncement to have a material effect on our consolidated financial statements.

In June 2011, the FASB issued ASU 2011-05 which provides new guidance on the presentation of comprehensive income (FASB ASC Topic 220) in financial statements. Entities are required to present total comprehensive income either in a single, continuous statement of comprehensive income or in two separate, but consecutive, statements. Under the single-statement approach, entities must include the components of net income, a total for net income, the components of other comprehensive income and a total for comprehensive income. Under the two-statement approach, entities must report an income statement and, immediately following, a statement of other comprehensive income. Under either method, entities must display adjustments for items reclassified from other comprehensive income to net income in both net income and other comprehensive income. The provisions for this pronouncement are effective for fiscal years, and interim periods within those years, beginning after December

30

15, 2011, with early adoption permitted. We will adopt this pronouncement for our fiscal year beginning January 1, 2012.

31

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in market risk from the information provided in Item 7A. "Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

Item 4. Controls and Procedures

A complete discussion of our controls and procedures is included in our Annual Report on Form 10-K for the year ended December 31, 2010.

Disclosure Controls and Procedures

Our management, under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of the end of the period covered by this report.  Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure and is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.  Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2011 at the reasonable assurance level.

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.  Further, the design of disclosure controls and internal control over financial reporting must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting

There have been no changes in our system of internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our fiscal quarter ended June 30, 2011, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

32

CORE LABORATORIES N.V.

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

See Note 6 of Consolidated Interim Financial Statements in Part I, Item 1.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

During the quarter ended June 30, 2011, we issued 213,936 shares of our common stock upon exchange by holders of $17.9 million aggregate principal amount of our Senior Exchangeable Notes and we issued 630,744 shares of our common stock upon the accelerated settlement of 1,648,040 of our warrants.  Such shares were issued in transactions exempt from registration under Section 3(a)(9) of the Securities Act of 1933, as amended.

The following table provides information about purchases of equity securities that are registered by us pursuant to Section 12 of the Exchange Act during the quarter ended June 30, 2011:

Period	Total Number of Shares Purchased	Average Price Paid Per Share		Total Number of Shares Purchased as Part of a Publicly Announced Program	Maximum Number of Shares That May Yet be Purchased Under the Program (3)
April 30, 2011 (1)	10,475	$	103.71	10,475	8,608,003
May 31, 2011 (2)	12,934	93.22		12,934	9,136,546
June 30, 2011	—	—		—	9,477,494
Total	23,409	$	97.92	23,409

(1) Contains 10,475 shares valued at approximately $1.1 million, or $103.71 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award in April 2011.

(2) Contains 12,934 shares valued at approximately $1.2 million, or $93.22 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award in May 2011.

(3) In connection with our initial public offering in September 1995, our shareholders authorized our Management Board to repurchase up to 10% of our issued share capital, the maximum allowed under Dutch law at the time, for a period of 18 months.  This authorization was renewed at subsequent annual or special shareholder meetings.  At our annual shareholders’ meeting on May 19, 2011, following a change in Dutch law that permitted us to repurchase up to 50% of our issued share capital in open market purchases, subject to shareholder approval, our shareholders authorized an extension to repurchase 10% of our issued share capital through November 19, 2012 and an additional 15.6% of our issued share capital until March 12, 2012 to fulfill obligations relating to the Notes or warrants. The repurchase of shares in the open market is at the discretion of management pursuant to this shareholder authorization.

33

Exhibit No.		Exhibit Title	Incorporated by reference from the following documents
3.1	-	Articles of Association of Core Laboratories N.V., as amended (including English translation)	Exhibit 3.1 filed on July 26, 2010 with 10-Q  (File No. 001-14273)
4.1	-	Warrant Confirmation Amendment Agreement between Core Laboratories N.V. and Citibank, N.A., dated May 4, 2011	Form 8-K, May 10, 2011 (File No. 001-14273)
4.2	-	Second Warrant Confirmation Amendment Agreement between Core Laboratories N.V. and Citibank, N.A., dated June 6, 2011	Form 8-K, June 9, 2011 (File No. 001-14273)
10.1	-	Amendment No. 1 to the Fifth Amended and Restated Credit Agreement, dated as of April 19, 2011, among Core Laboratories LP and the lenders party thereto and Bank of America, N.A., as administrative agent	Form 8-K, April 21, 2011 (File No. 001-14273)
31.1	-	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
31.2	-	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
32.1	-	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith
32.2	-	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith
101.INS	-	XBRL Instance Document	Filed herewith
101.SCH	-	XBRL Schema Document	Filed herewith
101.CAL	-	XBRL Calculation Linkbase Document	Filed herewith
101.LAB	-	XBRL Label Linkbase Document	Filed herewith
101.PRE	-	XBRL Presentation Linkbase Document	Filed herewith
101.DEF	-	XBRL Definition Linkbased Document	Filed herewith

34

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, Core Laboratories N.V., has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CORE LABORATORIES N.V.
		By:	Core Laboratories International B.V., its
			Managing Director
Date:	July 29, 2011	By:	/s/ Richard L. Bergmark
			Richard L. Bergmark
			Chief Financial Officer
			(Duly Authorized Officer and
			Principal Financial Officer)

35

EX-31.1

Certification

Exhibit 31.1

I, David M. Demshur, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Core Laboratories N.V. (the "Registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date:	July 29, 2011	By:	/s/ David M. Demshur
			David M. Demshur
			Chief Executive Officer

EX-31.2

Certification

Exhibit 31.2

I, Richard L. Bergmark, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Core Laboratories N.V. (the "Registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date:	July 29, 2011	By:	/s/ Richard L. Bergmark
			Richard L. Bergmark
			Chief Financial Officer

EX-32.1

Exhibit 32.1

Certification of

Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, David M. Demshur, Chief Executive Officer of Core Laboratories N.V. (the "Company"), hereby certify that the accompanying report on Form 10-Q for the quarter ended June 30, 2011, filed by the Company with the Securities and Exchange Commission on the date hereof fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, (the "Report").

I further certify that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	July 29, 2011	/s/ David M. Demshur
		Name: David M. Demshur
		Title: Chief Executive Officer

EX-32.2

Exhibit 32.2

Certification of

Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Richard L. Bergmark, Chief Financial Officer of Core Laboratories N.V. (the "Company"), hereby certify that the accompanying report on Form 10-Q for the quarter ended June 30, 2011, filed by the Company with the Securities and Exchange Commission on the date hereof fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, (the "Report").

I further certify that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	July 29, 2011	/s/ Richard L. Bergmark
		Name: Richard L. Bergmark
		Title: Chief Financial Officer

XML



Document and Entity Information Document	6 Months Ended
	Jun. 30, 2011
Entity Information [Line Items]
Entity Registrant Name	CORE LABORATORIES N V
Entity Central Index Key	0001000229
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2011
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding	45,612,898

XML



Debt Level 1 (Notes)

6 Months Ended

Jun. 30, 2011

Debt and Capital Lease Obligations [Abstract]

Debt Disclosure [Text Block]

DEBT

Debt is summarized in the following table (in thousands):

	June 30, 2011			December 31, 2010
	(Unaudited)
Senior exchangeable notes	$	91,930		$	156,407
Discount on senior exchangeable notes	(2,183		)	(8,864		)
Net senior exchangeable notes	$	89,747		$	147,543

In 2006, Core Laboratories LP, an entity 100% indirectly owned by Core Laboratories N.V., issued $300.0 million aggregate principal amount of Senior Exchangeable Notes (the "Notes") which are fully and unconditionally guaranteed by Core Laboratories N.V. and mature on October 31, 2011.  The Notes bear interest at a rate of 0.25% per year paid on a semi-annual basis.

With the additional amortization of the discount on the Notes, the effective interest rate is 7.48% for the three and six month period ended June 30, 2011, which resulted in additional non-cash interest expense of $1.8 million and $3.9 million for the three months ended June 30, 2011 and 2010, respectively, and $4.0 million and $7.7 million for the six months ended June 30, 2011 and 2010, respectively.  Each Note carries a $1,000 principal amount and is exchangeable into shares of Core Laboratories N.V. common stock under certain circumstances at an exchange price of $45.51 per share, or 21.9738 shares per Note.  Upon exchange, holders will receive cash for the principal amount plus any amount related to fractional shares, and any excess exchange value will be delivered in whole shares of Core Laboratories N.V. common stock at the completion of the valuation period as defined under our Notes agreement.  At June 30, 2011, the Notes were trading at 243% of their face value which is equivalent to $131.5 million of value in excess of the aggregate principal amount. At December 31, 2010, the Notes were trading at 197% of their face value which is equivalent to $151.7 million of value in excess of the aggregate principal amount.  There were 91,930 and 156,407 Notes outstanding at June 30, 2011 and December 31, 2010, respectively.

Under the terms of the Notes, defined criteria were met which allowed the Notes to be early exchanged during the second quarter of 2011, as it was during the first quarter of 2011, and as a result the equity component of the Notes at June 30, 2011 was classified as temporary equity.  This balance combined with the debt amount reflects the amount that could result in cash settlement upon exchange.  We received nine requests to exchange 17,909 Notes which were settled during the second quarter for $17.9 million in cash and 213,936 shares of our common stock, all of which were treasury shares, resulting in a loss of $0.2 million.  We also received five requests during the second quarter to exchange 888 Notes which we will settle during the third quarter upon completion of the requisite holding period per the Note Indenture agreement.

On April 19, 2011, we entered into an agreement for an amended revolving credit facility(the "Credit Facility") that we maintain that allowed for an aggregate borrowing capacity of $300.0 million at June 30, 2011. The Credit Facility also provided an option to increase the commitment under the Credit Facility to $350.0 million, if certain conditions are met.  The Credit Facility bears interest at variable rates from LIBOR plus 1.75% to a maximum of LIBOR plus 2.50%.  Any outstanding balance under the Credit Facility is due in December 2015 when the Credit Facility matures.   Interest payment terms are variable depending upon the specific type of borrowing under this facility. Our available capacity is reduced by outstanding letters of credit and performance guarantees and bonds totaling $14.5 million at June 30, 2011 relating to certain projects in progress.  Our available borrowing capacity under the Credit Facility at June 30, 2011 was $285.5 million.  As of June 30, 2011, we had $17.9 million of outstanding letters of credit and performance guarantees and bonds in addition to those under the Credit Facility.

The terms of the Credit Facility require us to meet certain financial and operational covenants. We believe that we were in compliance with all such covenants at June 30, 2011.  All of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility.

XML



Pensions and Other Postretirement Benefits Level 1 (Notes)

6 Months Ended

Jun. 30, 2011

PENSIONS AND OTHER POSTRETIREMENT BENEFITS [Abstract]

Pension and Other Postretirement Benefits Disclosure [Text Block]

PENSIONS AND OTHER POSTRETIREMENT BENEFITS

We provide a noncontributory defined benefit pension plan covering substantially all of our Dutch employees (the "Dutch Plan") who were hired prior to 2007 based on years of service and final pay or career average pay, depending on when the employee began participating. The benefits earned by the employees are immediately vested.  We fund the future obligations of the Dutch Plan by purchasing investment contracts from a large multi-national insurance company.  The investment contracts are purchased annually and expire after five years at which time they are replaced with new contracts that are adjusted to include changes in the benefit obligation for the current year and redemption of the expired contracts.  We determine the fair value of

these plan assets with the assistance of an actuary using observable inputs (Level 2).  We make annual premium payments to the insurance company, based on each employee's age and current salary.

The following table summarizes the components of net periodic pension cost under this plan for the three and six months ended June 30, 2011 and 2010 (in thousands):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2011			2010			2011			2010
	(Unaudited)						(Unaudited)
Service cost	$	352		$	304		$	687		$	627
Interest cost	454			352			886			728
Expected return on plan assets	(211		)	(111		)	(412		)	(230		)
Amortization of transition asset	(22		)	(22		)	(44		)	(44		)
Amortization of prior service cost	40			40			80			80
Amortization of net loss	84			95			168			189
Net periodic pension cost	$	697		$	658		$	1,365		$	1,350

During the six months ended June 30, 2011, we contributed approximately $1.9 million, as determined by the insurance company, to fund the estimated 2011 premiums on investment contracts held by the Dutch Plan.

We have adopted a non-qualified deferred compensation plan that allows certain highly compensated employees to defer a portion of their salary, commission and bonus, as well as the amount of any reductions in their deferrals under the deferred compensation plan for employees in the United States (the "Deferred Compensation Plan"), due to certain limitations imposed by the U.S. Internal Revenue Code of 1986, as amended (the "Internal Revenue Code").  The Deferred Compensation Plan also provides for employer contributions to be made on behalf of participants equal in amount to certain forfeitures of, and/or reductions in, employer contributions that participants could have received under the 401(k) Plan in the absence of certain limitations imposed by the Internal Revenue Code. Employer contributions to the Deferred Compensation Plan vest ratably over a period of five years. Contributions to the plan are invested in equity and other investment fund assets, and carried on the balance sheet at fair value.  A participant's plan benefits include the participant's deferrals, the vested portion of the employer's contributions, and deemed investment gains and losses on such amounts. The benefits under these contracts are fully vested and payment of benefits generally commences as of the last day of the month following the termination of services except that the payment of benefits for select executives generally commences on the first working day following a six month waiting period following the date of termination.

On a recurring basis, we use the market approach to value certain assets and liabilities at fair value at quoted prices in an active market (Level 1) and certain assets and liabilities using significant other observable inputs (Level 2). We do not have any assets or liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3). Gains and losses related to the fair value changes in the deferred compensation assets and liabilities are recorded in General and Administrative Expenses in the Consolidated Statements of Operations.  The following table summarizes the fair value balances (in thousands):

(Unaudited)			Fair Value Measurement at
			June 30, 2011
	Total		Level 1		Level 2		Level 3
Assets:
Deferred compensation plan trust assets	$	10,156	$	—	$	10,156	$	—
Liabilities:
Deferred compensation plan	$	15,203	$	2,932	$	12,271	$	—

			Fair Value Measurement at
			December 31, 2010
	Total		Level 1		Level 2		Level 3
Assets:
Deferred compensation plan trust assets	$	8,802	$	—	$	8,802	$	—
Liabilities:
Deferred compensation plan	$	13,063	$	2,275	$	10,788	$	—

XML



Commitments and Contingencies Level 1 (Notes)

6 Months Ended

Jun. 30, 2011

COMMITMENTS AND CONTINGENCIES [Abstract]

Commitments and Contingencies Disclosure [Text Block]

COMMITMENTS AND CONTINGENCIES

We have been and may from time to time be named as a defendant in legal actions that arise in the ordinary course of business.  These include, but are not limited to, employment-related claims and contractual disputes or claims for personal injury or property damage which occur in connection with the provision of our products and services.  Management does not currently believe that any of our pending contractual, employment-related, personal injury or property damage claims and disputes will have a material effect on our future results of operations, financial position or cash flow.

XML



Equity Level 1 (Notes)

6 Months Ended

Jun. 30, 2011

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

EQUITY

During the three months ended June 30, 2011, we repurchased 23,409 of our common shares for $2.3 million. These shares were surrendered to us pursuant to the terms of a stock-based compensation plan in consideration of the participants' tax burdens that may result from the issuance of common shares under that plan. During the six months ended June 30, 2011, we repurchased 574,174 of our common shares for $52.1 million. Included in this total were rights to 29,680 shares valued at $2.9 million that were surrendered to us pursuant to the terms of a stock-based compensation plan in consideration of the participants' tax burdens that may result from the issuance of common shares under that plan. Such common shares, unless canceled, may be reissued for a variety of purposes such as future acquisitions, employee stock awards, exchange of the Notes, or settlement of outstanding warrants.

In February and May 2011, we paid a quarterly dividend of $0.25 per share of common stock.  In addition, on July 12, 2011, we declared a quarterly dividend of $0.25 per share of common stock for shareholders of record on July 22, 2011 and payable on August 22, 2011.

In 2006, we sold warrants on our common shares, which have an exercise price of $61.25 per share, and will settle in January 2012.  The warrant agreement calls for the net value of these warrants to be settled with Core Laboratories N.V. common shares. 

In May 2011, we reached an agreement with the holder of the warrants to accelerate the settlement of 25% of the warrants. This agreement called for the daily settlement of 82,402 warrants using an exercise price which was adjusted based on the daily volume weighted average price. During May and June 2011, we settled 1,648,040 of the outstanding warrants using a calculated exercise price which averaged $59.57 during the period. These settlements resulted in the distribution of 630,744 shares of treasury stock. There was a second agreement entered into during the first week of June 2011 with the holder of the warrants to accelerate the settlement of an additional 25% of the original number of warrants during the months of June and July 2011. During June 2011, we settled 1,565,638 warrants using a calculated exercise price which averaged $60.24 during the period. We had the option to settle this tranche of warrants with cash or shares. These settlements resulted in a distribution of $57.8 million in cash during June 2011 with an additional $8.0 million in cash and 37,692 shares distributed in July 2011.

The following table summarizes our changes in equity for the six months ended June 30, 2011 (in thousands):

	Common		Additional Paid-In			Retained			Accumulated Other Comprehensive			Treasury			Non- Controlling			Total
(Unaudited)	Shares		Capital			Earnings			Income (Loss)			Stock			Interest			Equity
December 31, 2010	$	1,397	$	—		$	536,991		$	(6,207	)	$	(242,690	)	$	2,849		$	292,340
Stock options exercised	—		(1,377		)	—			—			1,618			—			241
Stock based-awards	—		307			—			—			5,616			—			5,923
Tax benefit of stock-based awards issued	—		2,289			—			—			—			—			2,289
Repurchase of common shares	—		—			—			—			(52,097		)	—			(52,097		)
Dividends paid	—		—			(22,709		)	—			—			—			(22,709		)
Equity component of short-term debt	—		6,681			—			—			—			—			6,681
Exchange of Senior Exchangeable Notes	—		(5,031		)	(40,311		)	—			43,452			—			(1,890		)
Settlement of warrants	—		(2,869		)	(101,078		)	—			38,188			—			(65,759		)
Non-controlling interest contribution	—		—			—			—			—			895			895
Non-controlling interest dividends	—		—			—			—			—			(240		)	(240		)
Comprehensive income:
Amortization of deferred pension costs, net of tax	—		—			—			152			—						152
Net income (loss)	—		—			86,741			—			—			(365		)	86,376
Total comprehensive income																		86,528
June 30, 2011	$	1,397	$	—		$	459,634		$	(6,055	)	$	(205,913	)	$	3,139		$	252,202

Comprehensive Income

The components of comprehensive income consisted of the following (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2011		2010		2011		2010
	(Unaudited)				(Unaudited)
Net income	$	40,384	$	34,362	$	86,376	$	66,648
Amortization of deferred pension costs, net of tax	76		86		152		171
Total comprehensive income	$	40,460	$	34,448	$	86,528	$	66,819

Accumulated other comprehensive income (loss) consisted of the following (in thousands):

	June 30, 2011			December 31, 2010
	(Unaudited)
Prior service cost	$	(793	)	$	(853	)
Transition asset	292			324
Unrecognized net actuarial loss	(5,554		)	(5,678		)
Total accumulated other comprehensive income (loss)	$	(6,055	)	$	(6,207	)

XML



Earnings per Share Level 1 (Notes)

6 Months Ended

Jun. 30, 2011

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

EARNINGS PER SHARE

We compute basic earnings per common share by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common and potential common shares include additional shares in the weighted average share calculations associated with the incremental effect of dilutive employee stock options, restricted stock awards and contingently issuable shares, as determined using the treasury stock method. The

following table summarizes the calculation of weighted average common shares outstanding used in the computation of diluted earnings per share (in thousands):

	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2011	2010	2011	2010
	(Unaudited)		(Unaudited)
Weighted average basic common shares outstanding	45,945	44,651	45,587	44,743
Effect of dilutive securities:
Stock options	23	55	24	56
Contingent shares	68	44	63	37
Restricted stock and other	230	568	274	550
Senior exchangeable notes	1,097	1,823	1,176	1,586
Warrants	1,299	816	1,818	424
Weighted average diluted common and potential common shares outstanding	48,662	47,957	48,942	47,396

In 2006, we sold warrants on our common shares, which have an exercise price of $61.25 per share, and will settle in January 2012.  The warrant agreement calls for the net value of these warrants to be settled with Core Laboratories N.V. common shares. 

Included in the table above are 1,299,000 and 816,000 shares which were added to the share count for the three months ended June 30, 2011 and 2010, respectively, and 1,818,000 and 424,000 shares which were added to the share count for the six months ended June 30, 2011 and 2010, respectively, because the average share price exceeded the strike price of the warrants.  These shares were included in calculating the impact to our dilutive earnings per share for the three and six months ended June 30, 2011 and 2010.

XML



Other (Income), net Level 1 (Notes)

6 Months Ended

Jun. 30, 2011

OTHER (INCOME), NET [Abstract]

Other Income and Other Expense Disclosure [Text Block]

OTHER (INCOME) EXPENSE, NET

The components of other (income) expense, net, were as follows (in thousands):

	Three Months Ended							Six Months Ended
	June 30,							June 30,
	2011				2010			2011			2010
	(Unaudited)							(Unaudited)
(Gain) loss on sale of assets	$	(75	)		$	39		$	(138	)	$	8
Foreign exchange (gain) loss	(9		)		1,712			(521		)	1,621
Interest income	(30		)		(130		)	(85		)	(142		)
Rents and royalties	(382		)		(218		)	(833		)	(700		)
Gain on insurance recovery	(69		)		—			(779		)	—
Legal entity realignment	711			711	—			711			—
Other, net	1				(115		)	(79		)	(297		)
Total other (income) expense, net	$	147			$	1,288		$	(1,724	)	$	490

During the third quarter of 2010, an office and laboratory facility was damaged by fire, resulting in the loss of the laboratory portion of the building, as well as some of the laboratory equipment.  The final settlement was reached in the first quarter of 2011, which resulted in a gain of $0.8 million.

Foreign exchange (gains) losses by currency are summarized in the following table (in thousands):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2011			2010			2011			2010
	(Unaudited)						(Unaudited)
British Pound	$	44		$	158		$	(47	)	$	416
Canadian Dollar	(124		)	149			(543		)	(236		)
Euro	41			1,619			(25		)	1,589
Mexican Peso	36			(14		)	142			94
Russian Ruble	(24		)	(69		)	(219		)	(15		)
Other currencies, net	18			(131		)	171			(227		)
Total (gain) loss	$	(9	)	$	1,712		$	(521	)	$	1,621

XML



Income Tax Expense Level 1 (Notes)

6 Months Ended

Jun. 30, 2011

INCOME TAX EXPENSE [Abstract]

Income Tax Disclosure [Text Block]

INCOME TAX EXPENSE

The effective tax rates for the three months ended June 30, 2011 and 2010 were 26.7% and 30.7%, respectively.  The effective tax rates for year to date 2011 and 2010 were 20.5% and 31.3%, respectively. Included in income tax expense is the reversal in the six months ended June 30, 2011 of $10.4 million in tax liabilities provided over the period of 2007-2010 as a result of recently concluded audits of prior year returns.  The liability reversal reflects the impact of positions sustained in certain audits.

XML



Segment Reporting Level 1 (Notes)

6 Months Ended

Jun. 30, 2011

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

SEGMENT REPORTING

We operate our business in three reportable segments:  (1) Reservoir Description, (2) Production Enhancement and (3) Reservoir Management.  These business segments provide different services and utilize different technologies.

• Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.

• Production Enhancement: Includes products and services relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.

• Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.

Results for these business segments are presented below.  We use the same accounting policies to prepare our business segment results as are used to prepare our Consolidated Financial Statements.  We evaluate performance based on income or loss before income tax, interest and other non-operating income (expense). All interest and other non-operating income (expense) is attributable to the Corporate & Other area and is not allocated to specific business segments. Summarized financial information concerning our segments is shown in the following table (in thousands):

(Unaudited)	Reservoir Description		Production Enhancement		Reservoir Management		Corporate & Other 1			Consolidated
Three Months Ended June 30, 2011
Revenues from unaffiliated customers	$	118,758	$	88,787	$	18,240	$	—		$	225,785
Inter-segment revenues	447		357		595		(1,399		)	—
Segment operating income	26,629		24,500		7,307		(633		)	57,803
Total assets	272,298		208,114		19,146		52,675			552,233
Capital expenditures	4,079		2,499		284		743			7,605
Depreciation and amortization	3,517		1,578		169		541			5,805
Three Months Ended June 30, 2010
Revenues from unaffiliated customers	$	106,528	$	79,717	$	12,657	$	—		$	198,902
Inter-segment revenues	248		419		427		(1,094		)	—
Segment operating income (loss)	25,074		26,152		3,672		(1,178		)	53,720
Total assets	258,759		190,512		14,245		189,145			652,661
Capital expenditures	4,600		720		219		1,002			6,541
Depreciation and amortization	3,523		1,626		166		451			5,766
Six Months Ended June 30, 2011
Revenues from unaffiliated customers	$	226,379	$	170,885	$	35,254	$	—		$	432,518
Inter-segment revenues	816		665		954		(2,435		)	—
Segment operating income (loss)	53,067		47,762		13,971		(498		)	114,302
Total assets	272,298		208,114		19,146		52,675			552,233
Capital expenditures	7,382		3,303		391		908			11,984
Depreciation and amortization	6,999		3,217		349		1,071			11,636
Six Months Ended June 30, 2010
Revenues from unaffiliated customers	$	210,621	$	148,561	$	28,057	$	—		$	387,239
Inter-segment revenues	548		713		715		(1,976		)	—
Segment operating income (loss)	50,215		47,095		9,292		(1,469		)	105,133
Total assets	258,759		190,512		14,245		189,145			652,661
Capital expenditures	9,929		1,392		257		1,118			12,696
Depreciation and amortization	7,030		3,249		324		917			11,520

(1) "Corporate & Other" represents those items that are not directly related to a particular segment and eliminations.

XML



Condensed Consolidating Financial Information Level 1 (Notes)

6 Months Ended

Jun. 30, 2011

CONDENSED CONSOLIDATING FINANCIAL INFORMATION [Abstract]

Schedule of Condensed Financial Statement [Text Block]

CONDENSED CONSOLIDATING FINANCIAL INFORMATION

Core Laboratories N.V. has fully and unconditionally guaranteed all of the Notes issued by Core Laboratories LP in 2006. Core Laboratories LP is an entity 100% indirectly owned by Core Laboratories N.V.

The following condensed consolidating financial information is included so that separate financial statements of Core Laboratories LP are not required to be filed with the U.S. Securities and Exchange Commission (the "SEC"). The condensed consolidating financial statements present investments in both consolidated and unconsolidated affiliates using the equity method of accounting.

The following condensed consolidating financial information presents: balance sheets as of June 30, 2011 and December 31, 2010, statements of operations for each of the three and six months ended June 30, 2011 and 2010 and the statements of cash flows for each of the six months ended June 30, 2011 and 2010 of (a) Core Laboratories N.V., parent/guarantor, (b) Core Laboratories LP, issuer of public debt securities guaranteed by Core Laboratories N.V., (c) the non-guarantor subsidiaries, (d) consolidating adjustments necessary to consolidate Core Laboratories N.V. and its subsidiaries and (e) Core Laboratories N.V. on a consolidated basis.

Condensed Consolidating Balance Sheets (Unaudited)
(In thousands)	June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	9,240	$	6,138	$	9,183	$	—		$	24,561
Accounts receivable, net	281		35,209		124,718		—			160,208
Inventories, net	—		4,264		38,244		—			42,508
Prepaid expenses and other current assets	6,122		8,632		12,660		—			27,414
Total current assets	15,643		54,243		184,805		—			254,691
PROPERTY, PLANT AND EQUIPMENT, net	—		20,921		84,205		—			105,126
GOODWILL AND INTANGIBLES, net	46,986		15,445		99,988		—			162,419
INTERCOMPANY RECEIVABLES	18,720		89,185		397,713		(505,618		)	—
INVESTMENT IN AFFILIATES	566,537		—		1,596,076		(2,161,801		)	812
DEFERRED TAX ASSET	2,453		—		5,978		(1,629		)	6,802
OTHER ASSETS	3,347		15,713		3,323		—			22,383
TOTAL ASSETS	$	653,686	$	195,507	$	2,372,088	$	(2,669,048	)	$	552,233
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	8,968	$	8,974	$	43,389	$	—		$	61,331
Short-term debt	—		89,747		—		—			89,747
Other accrued expenses	2,366		30,844		51,810		—			85,020
Total current liabilities	11,334		129,565		95,199		—			236,098
LONG-TERM DEBT	—		—		—		—			—
DEFERRED COMPENSATION	6,476		17,421		104		—			24,001
DEFERRED TAX LIABILITY	—		762		867		(1,629		)	—
INTERCOMPANY PAYABLES	372,606		—		133,012		(505,618		)	—
OTHER LONG-TERM LIABILITIES	14,207		2,963		20,579		—			37,749
Equity Component of Short-term Debt -Senior Exchangeable Notes	—		2,183		—		—			2,183
SHAREHOLDERS' EQUITY	249,063		42,613		2,119,188		(2,161,801		)	249,063
NON-CONTROLLING INTEREST	—		—		3,139		—			3,139
TOTAL EQUITY	249,063		42,613		2,122,327		(2,161,801		)	252,202
TOTAL LIABILITIES AND EQUITY	$	653,686	$	195,507	$	2,372,088	$	(2,669,048	)	$	552,233

Condensed Consolidating Balance Sheets
(In thousands)	December 31, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	11,162	$	88,612	$	34,106	$	—		$	133,880
Accounts receivable, net	10		33,637		121,079		—			154,726
Inventories, net	—		4,127		29,852		—			33,979
Prepaid expenses and other current assets	5,641		9,437		11,657		—			26,735
	16,813		135,813		196,694		—			349,320
PROPERTY, PLANT AND EQUIPMENT, net	—		21,139		83,084		—			104,223
GOODWILL AND INTANGIBLES, net	46,986		15,838		100,053		—			162,877
INTERCOMPANY RECEIVABLES	21,749		164,945		242,754		(429,448		)	—
INVESTMENT IN AFFILIATES	553,693		—		1,567,416		(2,120,414		)	695
DEFERRED TAX ASSET	2,810		—		6,436		(9,246		)	—
OTHER ASSETS	3,209		13,099		2,619		—			18,927
TOTAL ASSETS	$	645,260	$	350,834	$	2,199,056	$	(2,559,108	)	$	636,042
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	336	$	5,144	$	39,230	$	—		$	44,710
Short-term debt	—		147,543		—		—			147,543
Other accrued expenses	2,291		29,250		55,559		—			87,100
	2,627		181,937		94,789		—			279,353
DEFERRED COMPENSATION	6,159		14,981		101		—			21,241
DEFERRED TAX LIABILITY	—		11,444		—		(9,246		)	2,198
INTERCOMPANY PAYABLES	333,651		—		95,797		(429,448		)	—
OTHER LONG-TERM LIABILITIES	13,332		1,099		17,615		—			32,046
Equity Component of Short-term Debt -Senior Exchangeable Notes	—		8,864		—		—			8,864
SHAREHOLDERS' EQUITY	289,491		132,509		1,987,905		(2,120,414		)	289,491
NON-CONTROLLING INTEREST	—		—		2,849		—			2,849
TOTAL EQUITY	289,491		132,509		1,990,754		(2,120,414		)	292,340
TOTAL LIABILITIES AND EQUITY	$	645,260	$	350,834	$	2,199,056	$	(2,559,108	)	$	636,042

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	52,935		$	172,850		$	—		$	225,785
Intercompany revenue	409		6,314			30,838			(37,561		)	—
Earnings (loss) from consolidated affiliates	48,014		—			90,507			(138,521		)	—
Total revenue	48,423		59,249			294,195			(176,082		)	225,785
OPERATING EXPENSES
Operating costs	264		26,698			125,311			—			152,273
General and administrative expenses	1,971		7,784			2			—			9,757
Depreciation and amortization	—		1,599			4,206			—			5,805
Other (income) expense, net	814		3,664			29,915			(34,246		)	147
Operating income	45,374		19,504			134,761			(141,836		)	57,803
Loss on exchange of Senior Exchangeable Notes	—		210			—			—			210
Interest expense	—		24,256			—			(21,757		)	2,499
Income (loss) before income tax expense	45,374		(4,962		)	134,761			(120,079		)	55,094
Income tax expense (benefit)	4,923		(8,436		)	18,223			—			14,710
Net income	40,451		3,474			116,538			(120,079		)	40,384
Net income (loss) attributable to non-controlling interest	—		—			(67		)	—			(67		)
Net income (loss) attributable to Core Laboratories	$	40,451	$	3,474		$	116,605		$	(120,079	)	$	40,451

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Six Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—		$	100,735		$	331,783		$	—		$	432,518
Intercompany revenue	769			11,695			70,894			(83,358		)	—
Earnings (loss) from consolidated affiliates	86,708			—			70,803			(157,511		)	—
Total revenue	87,477			112,430			473,480			(240,869		)	432,518
OPERATING EXPENSES
Operating costs	558			51,997			236,468			—			289,023
General and administrative expenses	4,615			14,654			12			—			19,281
Depreciation and amortization	—			3,229			8,407			—			11,636
Other (income) expense, net	943			6,609			56,342			(65,618		)	(1,724		)
Operating income	81,361			35,941			172,251			(175,251		)	114,302
Loss on exchange of Senior Exchangeable Notes	—			839			—			—			839
Interest expense	—			83,009			—			(78,150		)	4,859
Income (loss) before income tax expense	81,361			(47,907		)	172,251			(97,101		)	108,604
Income tax expense (benefit)	(5,380		)	10,991			16,617			—			22,228
Net income	86,741			(58,898		)	155,634			(97,101		)	86,376
Net income (loss) attributable to non-controlling interest	—			—			(365		)	—			(365		)
Net income (loss) attributable to Core Laboratories	$	86,741		$	(58,898	)	$	155,999		$	(97,101	)	$	86,741

Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Six Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by (used in) operating activities	$	128,131		$	(14,422	)	$	(15,755	)	$	—	$	97,954
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—			(1,256		)	(10,728		)	—		(11,984		)
Patents and other intangibles	—			(16		)	(116		)	—		(132		)
Proceeds from sale of assets	—			34			137			—		171
Proceeds from insurance recovery	—			—			884			—		884
Premiums on life insurance	—			(1,243		)	—			—		(1,243		)
Net cash used in investing activities	—			(2,481		)	(9,823		)	—		(12,304		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt borrowings	—			(64,477		)	—			—		(64,477		)
Stock options exercised	241			—			—			—		241
Excess tax benefits from stock-based compensation	2,289			—			—			—		2,289
Debt financing costs	—			(1,094		)	—			—		(1,094		)
Settlement of Warrants	(57,777		)	—			—			—		(57,777		)
Non-controlling interest - contributions	—			—			895			—		895
Non-controlling interest - dividends	—			—			(240		)	—		(240		)
Dividends paid	(22,709		)	—			—			—		(22,709		)
Repurchase of common shares	(52,097		)	—			—			—		(52,097		)
Net cash provided by (used in) financing activities	(130,053		)	(65,571		)	655			—		(194,969		)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(1,922		)	(82,474		)	(24,923		)	—		(109,319		)
CASH AND CASH EQUIVALENTS, beginning of period	11,162			88,612			34,106			—		133,880
CASH AND CASH EQUIVALENTS, end of period	$	9,240		$	6,138		$	9,183		$	—	$	24,561

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	48,386	$	150,516	$	—		$	198,902
Intercompany revenue	379		7,619		35,451		(43,449		)	—
Earnings from consolidated affiliates	37,709		—		115,745		(153,454		)	—
Total revenue	38,088		56,005		301,712		(196,903		)	198,902
OPERATING EXPENSES
Operating costs	322		25,237		103,358		—			128,917
General and administrative expenses	2,147		7,060		4		—			9,211
Depreciation and amortization	—		1,554		4,212		—			5,766
Other (income) expense, net	992		3,411		29,884		(32,999		)	1,288
Operating income	34,627		18,743		164,254		(163,904		)	53,720
Loss on exchange of Senior Exchangeable Notes	—		—		—		—			—
Interest expense	—		4,112		2		—			4,114
Income before income tax expense	34,627		14,631		164,252		(163,904		)	49,606
Income tax expense (benefit)	411		5,992		8,841		—			15,244
Net income	34,216		8,639		155,411		(163,904		)	34,362
Net income attributable to non-controlling interest	—		—		146		—			146
Net income attributable to Core Laboratories	$	34,216	$	8,639	$	155,265	$	(163,904	)	$	34,216

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Six Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	93,547	$	293,692	$	—		$	387,239
Intercompany revenue	667		12,206		70,960		(83,833		)	—
Earnings from consolidated affiliates	72,898		—		216,504		(289,402		)	—
Total revenue	73,565		105,753		581,156		(373,235		)	387,239
OPERATING EXPENSES
Operating costs	712		50,221		203,572		—			254,505
General and administrative expenses	4,314		11,270		7		—			15,591
Depreciation and amortization	—		3,112		8,408		—			11,520
Other (income) expense, net	857		5,002		58,192		(63,561		)	490
Operating income	67,682		36,148		310,977		(309,674		)	105,133
Interest expense	—		8,167		6		—			8,173
Income before income tax expense	67,682		27,981		310,971		(309,674		)	96,960
Income tax expense (benefit)	1,261		11,474		17,577		—			30,312
Net income	66,421		16,507		293,394		(309,674		)	66,648
Net income attributable to non-controlling interest	—		—		227		—			227
Net income attributable to Core Laboratories	$	66,421	$	16,507	$	293,167	$	(309,674	)	$	66,421

Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Six Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by operating activities	$	54,349		$	44,964		$	12,047		$	—	$	111,360
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—			(2,918		)	(9,778		)	—		(12,696		)
Patents and other intangibles	—			—			(142		)	—		(142		)
Acquisitions, net of cash	—			(9,000		)	—			—		(9,000		)
Proceeds from sale of assets	—			11			114			—		125
Premiums on life insurance	—			(921		)	—			—		(921		)
Net cash used in investing activities	—			(12,828		)	(9,806		)	—		(22,634		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock options exercised	295			—			—			—		295
Excess tax benefit from stock-based payments	798			—			—			—		798
Non-controlling interest - dividends	—			—			(181		)	—		(181		)
Dividends paid	(5,375		)	—			—			—		(5,375		)
Repurchase of common shares	(91,686		)	—			—			—		(91,686		)
Net cash used in financing activities	(95,968		)	—			(181		)	—		(96,149		)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(41,619		)	32,136			2,060			—		(7,423		)
CASH AND CASH EQUIVALENTS, beginning of period	73,998			95,048			11,999			—		181,045
CASH AND CASH EQUIVALENTS, end of period	$	32,379		$	127,184		$	14,059		$	—	$	173,622

XML



Recent Accounting Pronouncements Level 1 (Notes)

6 Months Ended

Jun. 30, 2011

RECENT ACCOUNTING PRONOUNCEMENTS [Abstract]

Description of New Accounting Pronouncements Not yet Adopted [Text Block]

13. RECENT ACCOUNTING PRONOUNCEMENTS

In May 2011, the FASB issued ASU 2011-04) which relates to fair value measurement (FASB ASC Topic 820), which amends current guidance to achieve common fair value measurement and disclosure requirements in U.S. GAAP and International Financial Reporting Standards. The amendments generally represent clarification of FASB ASC Topic 820, but also include instances where a particular principle or requirement for measuring fair value or disclosing information about fair value measurements has changed. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. We will adopt this pronouncement for our fiscal year beginning January 1, 2012. We do not expect this pronouncement to have a material effect on our consolidated financial statements.

In June 2011, the FASB issued ASU 2011-05which provides new guidance on the presentation of comprehensive income (FASB ASC Topic 220) in financial statements. Entities are required to present total comprehensive income either in a single, continuous statement of comprehensive income or in two separate, but consecutive, statements. Under the single-statement approach, entities must include the components of net income, a total for net income, the components of other comprehensive income and a total for comprehensive income. Under the two-statement approach, entities must report an income statement and, immediately following, a statement of other comprehensive income. Under either method, entities must display adjustments for items reclassified from other comprehensive income to net income in both net income and other comprehensive income. The provisions for this pronouncement are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with early adoption permitted. We will adopt this pronouncement for our fiscal year beginning January 1, 2012.

XML



Statement of Financial Position Statement (USD $) In Thousands	Jun. 30, 2011	Dec. 31, 2010
Cash and Cash Equivalents, at Carrying Value	$ 24,561	$ 133,880
Accounts Receivable, Net	160,208	154,726
Inventory, Net	42,508	33,979
Prepaid Expense and Other Assets	27,414	26,735
TOTAL CURRENT ASSETS	254,691	349,320
Property, Plant and Equipment, Net	105,126	104,223
Intangible Assets, Net (Excluding Goodwill)	8,202	8,660
Goodwill	154,217	154,217
Deferred Tax Assets, Net, Noncurrent	6,802	0
Other Assets, Noncurrent	23,195	19,622
TOTAL ASSETS	552,233	636,042
Accounts Payable, Current	61,331	44,710
Employee-related Liabilities, Current	28,087	28,621
Sales and Excise Tax Payable, Current	9,116	7,796
Deferred Revenue, Current	22,830	20,181
Taxes Payable, Current	12,234	21,004
Convertible Debt, Current	89,747	147,543
Other Accrued Liabilities, Current	12,753	9,498
TOTAL CURRENT LIABILITIES	236,098	279,353
Deferred Compensation Liability, Classified, Noncurrent	24,001	21,241
Deferred Tax Liabilities, Noncurrent	0	2,198
Other Liabilities, Noncurrent	37,749	32,046
Commitments and Contingencies	0	0
Temporary Equity, Redemption Value	2,183	8,864
Preferred Stock, Value, Issued	0	0
Common Stock, Value, Issued	1,397	1,397
Additional Paid in Capital, Common Stock	0	0
Retained Earnings (Accumulated Deficit)	459,634	536,991
Accumulated Other Comprehensive Income (Loss), Net of Tax	(6,055)	(6,207)
Treasury shares (at cost), xxx at 2011 and 4,218,726 at 2010	(205,913)	(242,690)
Total Core Laboratories N.V. shareholders' equity	249,063	289,491
Stockholders' Equity Attributable to Noncontrolling Interest	3,139	2,849
TOTAL EQUITY	252,202	292,340
TOTAL LIABILITIES AND EQUITY	$ 552,233	$ 636,042

XML



Inventories (Tables)

6 Months Ended

Jun. 30, 2011

INVENTORIES [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consist of the following (in thousands):

	June 30, 2011		December 31, 2010
	(Unaudited)
Finished goods	$	31,843	$	24,476
Parts and materials	8,716		6,727
Work in progress	1,949		2,776
Total inventories, net	$	42,508	$	33,979

XML



Debt Level 3 (Tables)

6 Months Ended

Jun. 30, 2011

Debt and Capital Lease Obligations [Abstract]

Schedule of Long-term Debt Instruments [Table Text Block]

Debt is summarized in the following table (in thousands):

	June 30, 2011			December 31, 2010
	(Unaudited)
Senior exchangeable notes	$	91,930		$	156,407
Discount on senior exchangeable notes	(2,183		)	(8,864		)
Net senior exchangeable notes	$	89,747		$	147,543

XML



Pensions and Other Postretirement Benefits Level 3 (Tables)

6 Months Ended

Jun. 30, 2011

PENSIONS AND OTHER POSTRETIREMENT BENEFITS [Abstract]

Schedule of Net Benefit Costs [Table Text Block]

The following table summarizes the components of net periodic pension cost under this plan for the three and six months ended June 30, 2011 and 2010 (in thousands):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2011			2010			2011			2010
	(Unaudited)						(Unaudited)
Service cost	$	352		$	304		$	687		$	627
Interest cost	454			352			886			728
Expected return on plan assets	(211		)	(111		)	(412		)	(230		)
Amortization of transition asset	(22		)	(22		)	(44		)	(44		)
Amortization of prior service cost	40			40			80			80
Amortization of net loss	84			95			168			189
Net periodic pension cost	$	697		$	658		$	1,365		$	1,350

Fair Value, by Balance Sheet Grouping [Table Text Block]

he following table summarizes the fair value balances (in thousands):

(Unaudited)			Fair Value Measurement at
			June 30, 2011
	Total		Level 1		Level 2		Level 3
Assets:
Deferred compensation plan trust assets	$	10,156	$	—	$	10,156	$	—
Liabilities:
Deferred compensation plan	$	15,203	$	2,932	$	12,271	$	—

			Fair Value Measurement at
			December 31, 2010
	Total		Level 1		Level 2		Level 3
Assets:
Deferred compensation plan trust assets	$	8,802	$	—	$	8,802	$	—
Liabilities:
Deferred compensation plan	$	13,063	$	2,275	$	10,788	$	—

XML



Equity Level 3 (Tables)

6 Months Ended

Jun. 30, 2011

Equity [Abstract]

Schedule of Stockholders Equity [Table Text Block]

The following table summarizes our changes in equity for the six months ended June 30, 2011 (in thousands):

	Common		Additional Paid-In			Retained			Accumulated Other Comprehensive			Treasury			Non- Controlling			Total
(Unaudited)	Shares		Capital			Earnings			Income (Loss)			Stock			Interest			Equity
December 31, 2010	$	1,397	$	—		$	536,991		$	(6,207	)	$	(242,690	)	$	2,849		$	292,340
Stock options exercised	—		(1,377		)	—			—			1,618			—			241
Stock based-awards	—		307			—			—			5,616			—			5,923
Tax benefit of stock-based awards issued	—		2,289			—			—			—			—			2,289
Repurchase of common shares	—		—			—			—			(52,097		)	—			(52,097		)
Dividends paid	—		—			(22,709		)	—			—			—			(22,709		)
Equity component of short-term debt	—		6,681			—			—			—			—			6,681
Exchange of Senior Exchangeable Notes	—		(5,031		)	(40,311		)	—			43,452			—			(1,890		)
Settlement of warrants	—		(2,869		)	(101,078		)	—			38,188			—			(65,759		)
Non-controlling interest contribution	—		—			—			—			—			895			895
Non-controlling interest dividends	—		—			—			—			—			(240		)	(240		)
Comprehensive income:
Amortization of deferred pension costs, net of tax	—		—			—			152			—						152
Net income (loss)	—		—			86,741			—			—			(365		)	86,376
Total comprehensive income																		86,528
June 30, 2011	$	1,397	$	—		$	459,634		$	(6,055	)	$	(205,913	)	$	3,139		$	252,202

Schedule of Comprehensive Income (Loss) [Table Text Block]

The components of comprehensive income consisted of the following (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2011		2010		2011		2010
	(Unaudited)				(Unaudited)
Net income	$	40,384	$	34,362	$	86,376	$	66,648
Amortization of deferred pension costs, net of tax	76		86		152		171
Total comprehensive income	$	40,460	$	34,448	$	86,528	$	66,819

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Accumulated other comprehensive income (loss) consisted of the following (in thousands):

	June 30, 2011			December 31, 2010
	(Unaudited)
Prior service cost	$	(793	)	$	(853	)
Transition asset	292			324
Unrecognized net actuarial loss	(5,554		)	(5,678		)
Total accumulated other comprehensive income (loss)	$	(6,055	)	$	(6,207	)

XML



Earnings per Share Level 3 (Tables)

6 Months Ended

Jun. 30, 2011

Earnings Per Share [Abstract]

Schedule of Weighted Average Number of Shares [Table Text Block]

The

following table summarizes the calculation of weighted average common shares outstanding used in the computation of diluted earnings per share (in thousands):

	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2011	2010	2011	2010
	(Unaudited)		(Unaudited)
Weighted average basic common shares outstanding	45,945	44,651	45,587	44,743
Effect of dilutive securities:
Stock options	23	55	24	56
Contingent shares	68	44	63	37
Restricted stock and other	230	568	274	550
Senior exchangeable notes	1,097	1,823	1,176	1,586
Warrants	1,299	816	1,818	424
Weighted average diluted common and potential common shares outstanding	48,662	47,957	48,942	47,396

XML



Other (Income), net Level 3 (Tables)

6 Months Ended

Jun. 30, 2011

OTHER (INCOME), NET [Abstract]

ForeignCurrencyGainsLossesByCurrency [Table Text Block]

Foreign exchange (gains) losses by currency are summarized in the following table (in thousands):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2011			2010			2011			2010
	(Unaudited)						(Unaudited)
British Pound	$	44		$	158		$	(47	)	$	416
Canadian Dollar	(124		)	149			(543		)	(236		)
Euro	41			1,619			(25		)	1,589
Mexican Peso	36			(14		)	142			94
Russian Ruble	(24		)	(69		)	(219		)	(15		)
Other currencies, net	18			(131		)	171			(227		)
Total (gain) loss	$	(9	)	$	1,712		$	(521	)	$	1,621

Schedule of Other Operating Cost and Expense, by Component [Table Text Block]

The components of other (income) expense, net, were as follows (in thousands):

	Three Months Ended							Six Months Ended
	June 30,							June 30,
	2011				2010			2011			2010
	(Unaudited)							(Unaudited)
(Gain) loss on sale of assets	$	(75	)		$	39		$	(138	)	$	8
Foreign exchange (gain) loss	(9		)		1,712			(521		)	1,621
Interest income	(30		)		(130		)	(85		)	(142		)
Rents and royalties	(382		)		(218		)	(833		)	(700		)
Gain on insurance recovery	(69		)		—			(779		)	—
Legal entity realignment	711			711	—			711			—
Other, net	1				(115		)	(79		)	(297		)
Total other (income) expense, net	$	147			$	1,288		$	(1,724	)	$	490

XML



Segment Reporting Level 3 (Tables)

6 Months Ended

Jun. 30, 2011

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Summarized financial information concerning our segments is shown in the following table (in thousands):

(Unaudited)	Reservoir Description		Production Enhancement		Reservoir Management		Corporate & Other 1			Consolidated
Three Months Ended June 30, 2011
Revenues from unaffiliated customers	$	118,758	$	88,787	$	18,240	$	—		$	225,785
Inter-segment revenues	447		357		595		(1,399		)	—
Segment operating income	26,629		24,500		7,307		(633		)	57,803
Total assets	272,298		208,114		19,146		52,675			552,233
Capital expenditures	4,079		2,499		284		743			7,605
Depreciation and amortization	3,517		1,578		169		541			5,805
Three Months Ended June 30, 2010
Revenues from unaffiliated customers	$	106,528	$	79,717	$	12,657	$	—		$	198,902
Inter-segment revenues	248		419		427		(1,094		)	—
Segment operating income (loss)	25,074		26,152		3,672		(1,178		)	53,720
Total assets	258,759		190,512		14,245		189,145			652,661
Capital expenditures	4,600		720		219		1,002			6,541
Depreciation and amortization	3,523		1,626		166		451			5,766
Six Months Ended June 30, 2011
Revenues from unaffiliated customers	$	226,379	$	170,885	$	35,254	$	—		$	432,518
Inter-segment revenues	816		665		954		(2,435		)	—
Segment operating income (loss)	53,067		47,762		13,971		(498		)	114,302
Total assets	272,298		208,114		19,146		52,675			552,233
Capital expenditures	7,382		3,303		391		908			11,984
Depreciation and amortization	6,999		3,217		349		1,071			11,636
Six Months Ended June 30, 2010
Revenues from unaffiliated customers	$	210,621	$	148,561	$	28,057	$	—		$	387,239
Inter-segment revenues	548		713		715		(1,976		)	—
Segment operating income (loss)	50,215		47,095		9,292		(1,469		)	105,133
Total assets	258,759		190,512		14,245		189,145			652,661
Capital expenditures	9,929		1,392		257		1,118			12,696
Depreciation and amortization	7,030		3,249		324		917			11,520

XML



Condensed Consolidating Financial Information Level 3 (Tables)

6 Months Ended

Jun. 30, 2011

CONDENSED CONSOLIDATING FINANCIAL INFORMATION [Abstract]

Schedule of Condensed Financial Statements Balance Sheet [Table Text Block]

Condensed Consolidating Balance Sheets (Unaudited)
(In thousands)	June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	9,240	$	6,138	$	9,183	$	—		$	24,561
Accounts receivable, net	281		35,209		124,718		—			160,208
Inventories, net	—		4,264		38,244		—			42,508
Prepaid expenses and other current assets	6,122		8,632		12,660		—			27,414
Total current assets	15,643		54,243		184,805		—			254,691
PROPERTY, PLANT AND EQUIPMENT, net	—		20,921		84,205		—			105,126
GOODWILL AND INTANGIBLES, net	46,986		15,445		99,988		—			162,419
INTERCOMPANY RECEIVABLES	18,720		89,185		397,713		(505,618		)	—
INVESTMENT IN AFFILIATES	566,537		—		1,596,076		(2,161,801		)	812
DEFERRED TAX ASSET	2,453		—		5,978		(1,629		)	6,802
OTHER ASSETS	3,347		15,713		3,323		—			22,383
TOTAL ASSETS	$	653,686	$	195,507	$	2,372,088	$	(2,669,048	)	$	552,233
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	8,968	$	8,974	$	43,389	$	—		$	61,331
Short-term debt	—		89,747		—		—			89,747
Other accrued expenses	2,366		30,844		51,810		—			85,020
Total current liabilities	11,334		129,565		95,199		—			236,098
LONG-TERM DEBT	—		—		—		—			—
DEFERRED COMPENSATION	6,476		17,421		104		—			24,001
DEFERRED TAX LIABILITY	—		762		867		(1,629		)	—
INTERCOMPANY PAYABLES	372,606		—		133,012		(505,618		)	—
OTHER LONG-TERM LIABILITIES	14,207		2,963		20,579		—			37,749
Equity Component of Short-term Debt -Senior Exchangeable Notes	—		2,183		—		—			2,183
SHAREHOLDERS' EQUITY	249,063		42,613		2,119,188		(2,161,801		)	249,063
NON-CONTROLLING INTEREST	—		—		3,139		—			3,139
TOTAL EQUITY	249,063		42,613		2,122,327		(2,161,801		)	252,202
TOTAL LIABILITIES AND EQUITY	$	653,686	$	195,507	$	2,372,088	$	(2,669,048	)	$	552,233

Schedule of Condensed Financial Statements Prior Year Balance Sheet [Table Text Block]

Condensed Consolidating Balance Sheets
(In thousands)	December 31, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	11,162	$	88,612	$	34,106	$	—		$	133,880
Accounts receivable, net	10		33,637		121,079		—			154,726
Inventories, net	—		4,127		29,852		—			33,979
Prepaid expenses and other current assets	5,641		9,437		11,657		—			26,735
	16,813		135,813		196,694		—			349,320
PROPERTY, PLANT AND EQUIPMENT, net	—		21,139		83,084		—			104,223
GOODWILL AND INTANGIBLES, net	46,986		15,838		100,053		—			162,877
INTERCOMPANY RECEIVABLES	21,749		164,945		242,754		(429,448		)	—
INVESTMENT IN AFFILIATES	553,693		—		1,567,416		(2,120,414		)	695
DEFERRED TAX ASSET	2,810		—		6,436		(9,246		)	—
OTHER ASSETS	3,209		13,099		2,619		—			18,927
TOTAL ASSETS	$	645,260	$	350,834	$	2,199,056	$	(2,559,108	)	$	636,042
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	336	$	5,144	$	39,230	$	—		$	44,710
Short-term debt	—		147,543		—		—			147,543
Other accrued expenses	2,291		29,250		55,559		—			87,100
	2,627		181,937		94,789		—			279,353
DEFERRED COMPENSATION	6,159		14,981		101		—			21,241
DEFERRED TAX LIABILITY	—		11,444		—		(9,246		)	2,198
INTERCOMPANY PAYABLES	333,651		—		95,797		(429,448		)	—
OTHER LONG-TERM LIABILITIES	13,332		1,099		17,615		—			32,046
Equity Component of Short-term Debt -Senior Exchangeable Notes	—		8,864		—		—			8,864
SHAREHOLDERS' EQUITY	289,491		132,509		1,987,905		(2,120,414		)	289,491
NON-CONTROLLING INTEREST	—		—		2,849		—			2,849
TOTAL EQUITY	289,491		132,509		1,990,754		(2,120,414		)	292,340
TOTAL LIABILITIES AND EQUITY	$	645,260	$	350,834	$	2,199,056	$	(2,559,108	)	$	636,042

Schedule of Condensed Financial Statements Income Statement Quarter [Table Text Block]

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	52,935		$	172,850		$	—		$	225,785
Intercompany revenue	409		6,314			30,838			(37,561		)	—
Earnings (loss) from consolidated affiliates	48,014		—			90,507			(138,521		)	—
Total revenue	48,423		59,249			294,195			(176,082		)	225,785
OPERATING EXPENSES
Operating costs	264		26,698			125,311			—			152,273
General and administrative expenses	1,971		7,784			2			—			9,757
Depreciation and amortization	—		1,599			4,206			—			5,805
Other (income) expense, net	814		3,664			29,915			(34,246		)	147
Operating income	45,374		19,504			134,761			(141,836		)	57,803
Loss on exchange of Senior Exchangeable Notes	—		210			—			—			210
Interest expense	—		24,256			—			(21,757		)	2,499
Income (loss) before income tax expense	45,374		(4,962		)	134,761			(120,079		)	55,094
Income tax expense (benefit)	4,923		(8,436		)	18,223			—			14,710
Net income	40,451		3,474			116,538			(120,079		)	40,384
Net income (loss) attributable to non-controlling interest	—		—			(67		)	—			(67		)
Net income (loss) attributable to Core Laboratories	$	40,451	$	3,474		$	116,605		$	(120,079	)	$	40,451

Schedule of Condensed Financial Statements Income Statement YTD [Table Text Block]

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Six Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—		$	100,735		$	331,783		$	—		$	432,518
Intercompany revenue	769			11,695			70,894			(83,358		)	—
Earnings (loss) from consolidated affiliates	86,708			—			70,803			(157,511		)	—
Total revenue	87,477			112,430			473,480			(240,869		)	432,518
OPERATING EXPENSES
Operating costs	558			51,997			236,468			—			289,023
General and administrative expenses	4,615			14,654			12			—			19,281
Depreciation and amortization	—			3,229			8,407			—			11,636
Other (income) expense, net	943			6,609			56,342			(65,618		)	(1,724		)
Operating income	81,361			35,941			172,251			(175,251		)	114,302
Loss on exchange of Senior Exchangeable Notes	—			839			—			—			839
Interest expense	—			83,009			—			(78,150		)	4,859
Income (loss) before income tax expense	81,361			(47,907		)	172,251			(97,101		)	108,604
Income tax expense (benefit)	(5,380		)	10,991			16,617			—			22,228
Net income	86,741			(58,898		)	155,634			(97,101		)	86,376
Net income (loss) attributable to non-controlling interest	—			—			(365		)	—			(365		)
Net income (loss) attributable to Core Laboratories	$	86,741		$	(58,898	)	$	155,999		$	(97,101	)	$	86,741

Schedule of Condensed Financial Statements Cash Flow [Table Text Block]

Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Six Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by (used in) operating activities	$	128,131		$	(14,422	)	$	(15,755	)	$	—	$	97,954
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—			(1,256		)	(10,728		)	—		(11,984		)
Patents and other intangibles	—			(16		)	(116		)	—		(132		)
Proceeds from sale of assets	—			34			137			—		171
Proceeds from insurance recovery	—			—			884			—		884
Premiums on life insurance	—			(1,243		)	—			—		(1,243		)
Net cash used in investing activities	—			(2,481		)	(9,823		)	—		(12,304		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt borrowings	—			(64,477		)	—			—		(64,477		)
Stock options exercised	241			—			—			—		241
Excess tax benefits from stock-based compensation	2,289			—			—			—		2,289
Debt financing costs	—			(1,094		)	—			—		(1,094		)
Settlement of Warrants	(57,777		)	—			—			—		(57,777		)
Non-controlling interest - contributions	—			—			895			—		895
Non-controlling interest - dividends	—			—			(240		)	—		(240		)
Dividends paid	(22,709		)	—			—			—		(22,709		)
Repurchase of common shares	(52,097		)	—			—			—		(52,097		)
Net cash provided by (used in) financing activities	(130,053		)	(65,571		)	655			—		(194,969		)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(1,922		)	(82,474		)	(24,923		)	—		(109,319		)
CASH AND CASH EQUIVALENTS, beginning of period	11,162			88,612			34,106			—		133,880
CASH AND CASH EQUIVALENTS, end of period	$	9,240		$	6,138		$	9,183		$	—	$	24,561

Schedule of Condensed Financial Statements Income Statement Prior Year Quarter [Table Text Block]

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	48,386	$	150,516	$	—		$	198,902
Intercompany revenue	379		7,619		35,451		(43,449		)	—
Earnings from consolidated affiliates	37,709		—		115,745		(153,454		)	—
Total revenue	38,088		56,005		301,712		(196,903		)	198,902
OPERATING EXPENSES
Operating costs	322		25,237		103,358		—			128,917
General and administrative expenses	2,147		7,060		4		—			9,211
Depreciation and amortization	—		1,554		4,212		—			5,766
Other (income) expense, net	992		3,411		29,884		(32,999		)	1,288
Operating income	34,627		18,743		164,254		(163,904		)	53,720
Loss on exchange of Senior Exchangeable Notes	—		—		—		—			—
Interest expense	—		4,112		2		—			4,114
Income before income tax expense	34,627		14,631		164,252		(163,904		)	49,606
Income tax expense (benefit)	411		5,992		8,841		—			15,244
Net income	34,216		8,639		155,411		(163,904		)	34,362
Net income attributable to non-controlling interest	—		—		146		—			146
Net income attributable to Core Laboratories	$	34,216	$	8,639	$	155,265	$	(163,904	)	$	34,216

Schedule of Condensed Financial Statements Income Statement Prior Year YTD [Table Text Block]

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Six Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	93,547	$	293,692	$	—		$	387,239
Intercompany revenue	667		12,206		70,960		(83,833		)	—
Earnings from consolidated affiliates	72,898		—		216,504		(289,402		)	—
Total revenue	73,565		105,753		581,156		(373,235		)	387,239
OPERATING EXPENSES
Operating costs	712		50,221		203,572		—			254,505
General and administrative expenses	4,314		11,270		7		—			15,591
Depreciation and amortization	—		3,112		8,408		—			11,520
Other (income) expense, net	857		5,002		58,192		(63,561		)	490
Operating income	67,682		36,148		310,977		(309,674		)	105,133
Interest expense	—		8,167		6		—			8,173
Income before income tax expense	67,682		27,981		310,971		(309,674		)	96,960
Income tax expense (benefit)	1,261		11,474		17,577		—			30,312
Net income	66,421		16,507		293,394		(309,674		)	66,648
Net income attributable to non-controlling interest	—		—		227		—			227
Net income attributable to Core Laboratories	$	66,421	$	16,507	$	293,167	$	(309,674	)	$	66,421

Schedule of Condensed Financial Statements Cash Flow Prior Year [Table Text Block]

Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Six Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by operating activities	$	54,349		$	44,964		$	12,047		$	—	$	111,360
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—			(2,918		)	(9,778		)	—		(12,696		)
Patents and other intangibles	—			—			(142		)	—		(142		)
Acquisitions, net of cash	—			(9,000		)	—			—		(9,000		)
Proceeds from sale of assets	—			11			114			—		125
Premiums on life insurance	—			(921		)	—			—		(921		)
Net cash used in investing activities	—			(12,828		)	(9,806		)	—		(22,634		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock options exercised	295			—			—			—		295
Excess tax benefit from stock-based payments	798			—			—			—		798
Non-controlling interest - dividends	—			—			(181		)	—		(181		)
Dividends paid	(5,375		)	—			—			—		(5,375		)
Repurchase of common shares	(91,686		)	—			—			—		(91,686		)
Net cash used in financing activities	(95,968		)	—			(181		)	—		(96,149		)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(41,619		)	32,136			2,060			—		(7,423		)
CASH AND CASH EQUIVALENTS, beginning of period	73,998			95,048			11,999			—		181,045
CASH AND CASH EQUIVALENTS, end of period	$	32,379		$	127,184		$	14,059		$	—	$	173,622

XML



Inventories Inventories (Details) (USD $) In Thousands	Jun. 30, 2011	Dec. 31, 2010
Inventory, Finished Goods	$ 31,843	$ 24,476
Inventory, Raw Materials and Purchased Parts, Net of Reserves	8,716	6,727
Inventory, Work in Process	1,949	2,776
Inventory, Net	$ 42,508	$ 33,979

XML



Goodwill and Intangibles (Details) (USD $) In Millions, unless otherwise specified	6 Months Ended
	Jun. 30, 2010
Goodwill [Line Items]
Business Acquisition, Cost of Acquired Entity, Purchase Price	$ 9.0
Goodwill, Acquired During Period	5.6
Acquired Finite-lived Intangible Asset, Amount	$ 3.2
Finite-Lived Intangible Assets, Useful Life, Minimum	36
Finite-Lived Intangible Assets, Useful Life, Maximum	60

XML



Balance Sheet Parenthetical Parentheticals (USD $) In Thousands, except Share data	Jun. 30, 2011	Dec. 31, 2010
Allowance for Doubtful Accounts Receivable, Current	$ 3,536	$ 3,396
Common Stock, Par or Stated Value Per Share	$ 0.02	$ 0.02
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	49,739,912	49,739,912
Common Stock, Shares, Outstanding	46,483,989	45,521,186
Treasury Stock, Shares	3,255,923	4,218,726
Preferred Stock, Par or Stated Value Per Share	$ 0.02	$ 0.02
Preferred Stock, Shares Authorized	6,000,000	6,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

XML



Debt Level 4 (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Dec. 31, 2010
Debt Instrument [Line Items]
Loss on exchange of Senior Exchangeable Notes	$ (210,000)	$ 0	$ (839,000)	$ 0
Line of Credit Facility, Current Borrowing Capacity	300,000,000		300,000,000
Line of Credit Facility, Maximum Borrowing Capacity	350,000,000		350,000,000
Performance bonds under credit facility	14,500,000		14,500,000
Line of Credit Facility, Remaining Borrowing Capacity	285,500,000		285,500,000
Performance Bonds	17,900,000		17,900,000
Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.75%		1.75%
Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.50%		2.50%
Debt Conversion Requested 2 [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
NumberOfRequestsForConversionOfDebt		5
NumberOfDebtInstrumentsConverted			888
Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	300,000,000		300,000,000
Debt Instrument, Maturity Date			Oct. 31, 2011
Debt Instrument, Interest Rate, Stated Percentage	0.25%		0.25%
Debt Instrument, Interest Rate, Effective Percentage	7.48%		7.48%
Debt Instrument, Unamortized Discount	(2,183,000)		(2,183,000)		(8,864,000)
Long-term Debt, Gross	91,930,000		91,930,000		156,407,000
Amortization of Debt Discount (Premium)	1,800,000	3,900,000	4,000,000	7,700,000
FaceValueOfDebtPerInstrument			1,000
Debt Instrument, Convertible, Conversion Price	$ 45.51		$ 45.51
Debt Instrument, Convertible, Number of Equity Instruments			21.9738
PercentNotesTradingAboveFaceValue	243.00%		243.00%		197.00%
VarianceTradeValueToFaceValue	131,500,000		131,500,000		151,700,000
Number of Debt Instruments Outstanding	91,930		91,930		156,407
NumberOfRequestsForConversionOfDebt			9
NumberOfDebtInstrumentsConverted			17,909
Debt Conversion, Converted Instrument, Amount			17,900,000
Debt Conversion, Converted Instrument, Shares Issued			213,936
Loss on exchange of Senior Exchangeable Notes			200,000
Long-term Debt	$ 89,747,000		$ 89,747,000		$ 147,543,000

XML



Pensions and Other Postretirement Benefits Level 4 (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Contributions by Employer			$ 1,900,000
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	352,000	304,000	687,000	627,000
Defined Benefit Plan, Interest Cost	454,000	352,000	886,000	728,000
Defined Benefit Plan, Expected Return on Plan Assets	(211,000)	(111,000)	(412,000)	(230,000)
Defined Benefit Plan, Amortization of Transition Obligations (Assets)	(22,000)	(22,000)	(44,000)	(44,000)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	40,000	40,000	80,000	80,000
Defined Benefit Plan, Amortization of Gains (Losses)	84,000	95,000	168,000	189,000
Defined Benefit Plan, Net Periodic Benefit Cost	$ 697,000	$ 658,000	$ 1,365,000	$ 1,350,000

XML



Pensions and Other Postretirement Benefits Fair Value Measurement (Details) (USD $) In Thousands	Jun. 30, 2011	Dec. 31, 2010
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	$ 10,156	$ 8,802
Liabilities, Fair Value Disclosure	15,203	13,063
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	0	0
Liabilities, Fair Value Disclosure	2,932	2,275
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	10,156	8,802
Liabilities, Fair Value Disclosure	12,271	10,788
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	0	0
Liabilities, Fair Value Disclosure	$ 0	$ 0

XML



Equity Level 4 (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Dec. 31, 2010
Common Stock, Value, Issued	$ 1,397,000		$ 1,397,000		$ 1,397,000
Stock Issued During Period, Value, Stock Options Exercised			241,000
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures			5,923,000
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation			2,289,000
Stock Repurchased During Period, Value			(52,097,000)
Treasury Stock, Shares, Acquired	23,409		574,174
Dividends			(22,709,000)
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments			6,681,000
Stock Issued During Period, Value, Conversion of Convertible Securities			(1,890,000)
Settlement of Warrants Cash and Accrued			(65,759,000)
Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest			895,000
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders			(240,000)
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Recognized in Net Periodic Pension Cost, Net of Tax	76,000	86,000	152,000	171,000
Net income	40,384,000	34,362,000	86,376,000	66,648,000
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	40,460,000	34,448,000	86,528,000	66,819,000
Treasury Stock, Value, Acquired, Cost Method	2,300,000		52,100,000
TreasurySharesAcquiredTaxBurden			29,680
TreasurySharesAcquiredValueTaxBurden			2,900,000
Cash dividends per share	$ 0.25	$ 0.06	$ 0.50	$ 0.12
Common Stock, Dividends, Per Share, Declared	$ 0.25
Retained Earnings (Accumulated Deficit)	459,634,000		459,634,000		536,991,000
Accumulated Other Comprehensive Income (Loss), Net of Tax	(6,055,000)		(6,055,000)		(6,207,000)
Treasury Stock, Value	205,913,000		205,913,000		242,690,000
Stockholders' Equity Attributable to Noncontrolling Interest	3,139,000		3,139,000		2,849,000
TOTAL EQUITY	252,202,000		252,202,000		292,340,000
Common Stock [Member]
Common Stock, Value, Issued	1,397,000		1,397,000		1,397,000
Stock Issued During Period, Value, Stock Options Exercised			0
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures			0
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation			0
Stock Repurchased During Period, Value			0
Dividends			0
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments			0
Stock Issued During Period, Value, Conversion of Convertible Securities			0
Settlement of Warrants Cash and Accrued			0
Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest			0
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders			0
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Recognized in Net Periodic Pension Cost, Net of Tax			0
Net income			0
Additional Paid-in Capital [Member]
Additional Paid in Capital	0		0		0
Stock Issued During Period, Value, Stock Options Exercised			(1,377,000)
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures			307,000
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation			2,289,000
Stock Repurchased During Period, Value			0
Dividends			0
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments			6,681,000
Stock Issued During Period, Value, Conversion of Convertible Securities			(5,031,000)
Settlement of Warrants Cash and Accrued			(2,869,000)
Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest			0
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders			0
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Recognized in Net Periodic Pension Cost, Net of Tax			0
Net income			0
Retained Earnings [Member]
Stock Issued During Period, Value, Stock Options Exercised			0
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures			0
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation			0
Stock Repurchased During Period, Value			0
Dividends			(22,709,000)
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments			0
Stock Issued During Period, Value, Conversion of Convertible Securities			(40,311,000)
Settlement of Warrants Cash and Accrued			(101,078,000)
Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest			0
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders			0
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Recognized in Net Periodic Pension Cost, Net of Tax			0
Net income			86,741,000
Retained Earnings (Accumulated Deficit)	459,634,000		459,634,000		536,991,000
Accumulated Other Comprehensive Income (Loss) [Member]
Stock Issued During Period, Value, Stock Options Exercised			0
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures			0
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation			0
Stock Repurchased During Period, Value			0
Dividends			0
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments			0
Stock Issued During Period, Value, Conversion of Convertible Securities			0
Settlement of Warrants Cash and Accrued			0
Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest			0
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders			0
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Recognized in Net Periodic Pension Cost, Net of Tax			152,000
Net income			0
Accumulated Other Comprehensive Income (Loss), Net of Tax	(6,055,000)		(6,055,000)		(6,207,000)
Treasury Stock [Member]
Stock Issued During Period, Value, Stock Options Exercised			1,618,000
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures			5,616,000
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation			0
Stock Repurchased During Period, Value			(52,097,000)
Dividends			0
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments			0
Stock Issued During Period, Value, Conversion of Convertible Securities			43,452,000
Settlement of Warrants Cash and Accrued			38,188,000
Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest			0
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders			0
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Recognized in Net Periodic Pension Cost, Net of Tax			0
Net income			0
Treasury Stock, Value	(205,913,000)		(205,913,000)		(242,690,000)
Noncontrolling Interest [Member]
Stock Issued During Period, Value, Stock Options Exercised			0
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures			0
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation			0
Stock Repurchased During Period, Value			0
Dividends			0
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments			0
Stock Issued During Period, Value, Conversion of Convertible Securities			0
Settlement of Warrants Cash and Accrued			0
Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest			895,000
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders			(240,000)
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Recognized in Net Periodic Pension Cost, Net of Tax
Net income			(365,000)
Stockholders' Equity Attributable to Noncontrolling Interest	$ 3,139,000		$ 3,139,000		$ 2,849,000

XML



Equity Comprehensive Income (Details) (USD $) In Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Dec. 31, 2010
Prior service cost	$ (793)		$ (793)		$ (853)
Transition asset	292		292		324
Unrecognized net actuarial loss	(5,554)		(5,554)		(5,678)
Net income	40,384	34,362	86,376	66,648
Amortization of deferred pension costs, net of tax	76	86	152	171
Total comprehensive income	40,460	34,448	86,528	66,819
Total accumulated other comprehensive income (loss)	$ (6,055)		$ (6,055)		$ (6,207)

XML



Equity Warrants (Details) (USD $)	6 Months Ended
	Jun. 30, 2011
Warrants Settled Per Day	82,402
Class of Warrant or Right Average Excercise Price	$ 61.25
WarrantSettlement1 [Member]
Warrants Settled	$ 1,648,040
Class of Warrant or Right Average Excercise Price	$ 59.57
Shares Issued to Settle Warrants	630,744
Warrant Settlement 2 [Member]
Warrants Settled Accrued Shares	37,692
Warrants Settled	1,565,638
Class of Warrant or Right Average Excercise Price	$ 60.24
Warrants Settled Cash	57,800,000
Warrants Settled Cash Accrued	$ 8,000,000

XML



Earnings per Share Level 4 (Details) (USD $) In Thousands, except Per Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Class of Warrant or Right Average Excercise Price			$ 61.25
Weighted Average Number of Shares Outstanding, Basic	45,945	44,651	45,587	44,743
Incremental Common Shares Attributable to Stock Options	23	55	24	56
Incremental Common Shares Attributable to Contingently Issuable Shares	68	44	63	37
Weighted Average Number of Shares, Restricted Stock	230	568	274	550
Incremental Common Shares Attributable to Conversion of Debt Securities	1,097	1,823	1,176	1,586
Incremental Common Shares Attributable to Call Options and Warrants	1,299	816	1,818	424
Weighted Average Number of Shares Outstanding, Diluted	48,662	47,957	48,942	47,396

XML



Other (Income), net Level 4 (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Gains (Losses) on Sales of Assets [Member]
Component of Operating Other Cost and Expense [Line Items]
Other Nonoperating Income (Expense)	$ (75)	$ 39	$ (138)	$ 8
Foreign Currency Gain (Loss) [Member]
Component of Operating Other Cost and Expense [Line Items]
Other Nonoperating Income (Expense)	(9)	1,712	(521)	1,621
Other Operating Expense [Member]
Component of Operating Other Cost and Expense [Line Items]
Other Nonoperating Income (Expense)	1	(115)	(79)	(297)
Gain on Business Interruption Insurance Recovery			800,000
Interest Income [Member]
Component of Operating Other Cost and Expense [Line Items]
Other Nonoperating Income (Expense)	(30)	(130)	(85)	(142)
Rents And Royalties Income Loss [Member]
Component of Operating Other Cost and Expense [Line Items]
Other Nonoperating Income (Expense)	(382)	(218)	(833)	(700)
gain loss on insurance recovery [Member]
Component of Operating Other Cost and Expense [Line Items]
Other Nonoperating Income (Expense)	(69)	0	(779)	0
Legal entity realignment [Member]
Component of Operating Other Cost and Expense [Line Items]
Other Nonoperating Income (Expense)	711	0	711	0
Component of Other Income, Nonoperating, Name [Domain]
Component of Operating Other Cost and Expense [Line Items]
Other Nonoperating Income (Expense)	$ 147	$ 1,288	$ (1,724)	$ 490

XML



Other (Income), net Foreign Currency (Gain ) Loss by Currency (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Foreign Currency Transaction Gain (Loss), before Tax	$ (9)	$ 1,712	$ (521)	$ 1,621
British Pound [Member]
Foreign Currency Transaction Gain (Loss), before Tax	44	158	(47)	416
Canadian Dollar [Member]
Foreign Currency Transaction Gain (Loss), before Tax	(124)	149	(543)	(236)
Euro [Member]
Foreign Currency Transaction Gain (Loss), before Tax	41	1,619	(25)	1,589
Mexican Peso [Member]
Foreign Currency Transaction Gain (Loss), before Tax	36	(14)	142	94
Russian Ruble [Member]
Foreign Currency Transaction Gain (Loss), before Tax	(24)	(69)	(219)	(15)
Other Currencies Net [Member]
Foreign Currency Transaction Gain (Loss), before Tax	$ 18	$ (131)	$ 171	$ (227)

XML



Income Tax Expense Level 4 (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
INCOME TAX EXPENSE [Abstract]
Effective Income Tax Rate, Continuing Operations	26.70%	30.70%	20.50%	31.30%
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	$ 10.4		$ 10.4

XML



Statement of Income Statement (USD $) In Thousands, except Per Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
REVENUE:
Services	$ 169,756	$ 153,010	$ 322,870	$ 296,452
Product sales	56,029	45,892	109,648	90,787
Total Revenue	225,785	198,902	432,518	387,239
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below	112,001	96,411	212,733	191,768
Cost of product sales, exclusive of depreciation expense shown below	40,272	32,506	76,290	62,737
General and Administrative Expense, Excluding Depreciation	9,757	9,211	19,281	15,591
Depreciation	5,507	5,430	11,047	10,849
Amortization	298	336	589	671
Other (income), net	147	1,288	(1,724)	490
OPERATING INCOME	57,803	53,720	114,302	105,133
Loss on exchange of Senior Exchangeable Notes	210	0	839	0
Interest expense	2,499	4,114	4,859	8,173
Income before income tax expense	55,094	49,606	108,604	96,960
Income Tax Expense (Benefit)	14,710	15,244	22,228	30,312
Net income	40,384	34,362	86,376	66,648
Net Income (Loss) Attributable to Non-controlling Interest	(67)	146	(365)	227
Net income attributable to Core Laboratories N.V.	$ 40,451	$ 34,216	$ 86,741	$ 66,421
EARNINGS PER SHARE INFORMATION:
Basic earnings per share attributable to Core Laboratories N.V.	$ 0.88	$ 0.77	$ 1.90	$ 1.48
Diluted earnings per share attributable to Core Laboratories N.V.	$ 0.83	$ 0.71	$ 1.77	$ 1.40
Cash dividends per share	$ 0.25	$ 0.06	$ 0.50	$ 0.12
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	45,945	44,651	45,587	44,743
Diluted	48,662	47,957	48,942	47,396

XML



Segment Reporting Level 4 (Details) (USD $) In Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Dec. 31, 2010
Segment Reporting Information [Line Items]
TOTAL ASSETS	$ 552,233	$ 652,661	$ 552,233	$ 652,661	$ 636,042
Capital expenditures	7,605	6,541	11,984	12,696
Depreciation and amortization	5,805	5,766	11,636	11,520
Total Revenue	225,785	198,902	432,518	387,239
Segment Reporting Information, Intersegment Revenue	0	0	0	0
OPERATING INCOME	57,803	53,720	114,302	105,133
Operating Segment Reservoir Description [Member]
Segment Reporting Information [Line Items]
TOTAL ASSETS	272,298	258,759	272,298	258,759
Capital expenditures	4,079	4,600	7,382	9,929
Depreciation and amortization	3,517	3,523	6,999	7,030
Total Revenue	118,758	106,528	226,379	210,621
Segment Reporting Information, Intersegment Revenue	447	248	816	548
OPERATING INCOME	26,629	25,074	53,067	50,215
Operating Segment Production Enhancement [Member]
Segment Reporting Information [Line Items]
TOTAL ASSETS	208,114	190,512	208,114	190,512
Capital expenditures	2,499	720	3,303	1,392
Depreciation and amortization	1,578	1,626	3,217	3,249
Total Revenue	88,787	79,717	170,885	148,561
Segment Reporting Information, Intersegment Revenue	357	419	665	713
OPERATING INCOME	24,500	26,152	47,762	47,095
Operating Segment Reservoir Management [Member]
Segment Reporting Information [Line Items]
TOTAL ASSETS	19,146	14,245	19,146	14,245
Capital expenditures	284	219	391	257
Depreciation and amortization	169	166	349	324
Total Revenue	18,240	12,657	35,254	28,057
Segment Reporting Information, Intersegment Revenue	595	427	954	715
OPERATING INCOME	7,307	3,672	13,971	9,292
Operating Segment Corporate And Other [Member]
Segment Reporting Information [Line Items]
TOTAL ASSETS	52,675	189,145	52,675	189,145
Capital expenditures	743	1,002	908	1,118
Depreciation and amortization	541	451	1,071	917
Total Revenue	0	0	0	0
Segment Reporting Information, Intersegment Revenue	(1,399)	(1,094)	(2,435)	(1,976)
OPERATING INCOME	$ (633)	$ (1,178)	$ (498)	$ (1,469)

XML



Condensed Consolidating Financial Information Level 4 (Details) (USD $) In Thousands	Jun. 30, 2011	Dec. 31, 2010	Jun. 30, 2010	Dec. 31, 2009
Condensed Financial Statements, Captions [Line Items]
Cash and Cash Equivalents, at Carrying Value	$ 24,561	$ 133,880	$ 173,622	$ 181,045
Accounts Receivable, Net	160,208	154,726
Inventory, Net	42,508	33,979
Prepaid Expense and Other Assets	27,414	26,735
TOTAL CURRENT ASSETS	254,691	349,320
Property, Plant and Equipment, Net	105,126	104,223
Intangible Assets And Goodwill	162,419	162,877
Due from Affiliates	0	0
Equity Method Investments	812	695
Deferred Tax Assets, Net, Noncurrent	6,802	0
Other Assets Noncurrent less Investments	22,383	18,927
TOTAL ASSETS	552,233	636,042	652,661
Accounts Payable, Current	61,331	44,710
Convertible Debt, Current	89,747	147,543
Accrued Liabilities, Current	85,020	87,100
TOTAL CURRENT LIABILITIES	236,098	279,353
Convertible Debt, Noncurrent	0
Deferred Compensation Liability, Classified, Noncurrent	24,001	21,241
Deferred Tax Liabilities, Noncurrent	0	2,198
Due to Affiliate, Noncurrent	0	0
Other Liabilities, Noncurrent	37,749	32,046
Temporary Equity, Redemption Value	2,183	8,864
Total Core Laboratories N.V. shareholders' equity	249,063	289,491
Stockholders' Equity Attributable to Noncontrolling Interest	3,139	2,849
TOTAL EQUITY	252,202	292,340
TOTAL LIABILITIES AND EQUITY	552,233	636,042
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Cash and Cash Equivalents, at Carrying Value	9,240	11,162	32,379	73,998
Accounts Receivable, Net	281	10
Inventory, Net	0	0
Prepaid Expense and Other Assets	6,122	5,641
TOTAL CURRENT ASSETS	15,643	16,813
Property, Plant and Equipment, Net	0	0
Intangible Assets And Goodwill	46,986	46,986
Due from Affiliates	18,720	21,749
Equity Method Investments	566,537	553,693
Deferred Tax Assets, Net, Noncurrent	2,453	2,810
Other Assets Noncurrent less Investments	3,347	3,209
TOTAL ASSETS	653,686	645,260
Accounts Payable, Current	8,968	336
Convertible Debt, Current	0	0
Accrued Liabilities, Current	2,366	2,291
TOTAL CURRENT LIABILITIES	11,334	2,627
Convertible Debt, Noncurrent	0
Deferred Compensation Liability, Classified, Noncurrent	6,476	6,159
Deferred Tax Liabilities, Noncurrent	0	0
Due to Affiliate, Noncurrent	372,606	333,651
Other Liabilities, Noncurrent	14,207	13,332
Temporary Equity, Redemption Value	0	0
Total Core Laboratories N.V. shareholders' equity	249,063	289,491
Stockholders' Equity Attributable to Noncontrolling Interest	0	0
TOTAL EQUITY	249,063	289,491
TOTAL LIABILITIES AND EQUITY	653,686	645,260
Subsidiaries Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Cash and Cash Equivalents, at Carrying Value	6,138	88,612	127,184	95,048
Accounts Receivable, Net	35,209	33,637
Inventory, Net	4,264	4,127
Prepaid Expense and Other Assets	8,632	9,437
TOTAL CURRENT ASSETS	54,243	135,813
Property, Plant and Equipment, Net	20,921	21,139
Intangible Assets And Goodwill	15,445	15,838
Due from Affiliates	89,185	164,945
Equity Method Investments	0	0
Deferred Tax Assets, Net, Noncurrent	0	0
Other Assets Noncurrent less Investments	15,713	13,099
TOTAL ASSETS	195,507	350,834
Accounts Payable, Current	8,974	5,144
Convertible Debt, Current	89,747	147,543
Accrued Liabilities, Current	30,844	29,250
TOTAL CURRENT LIABILITIES	129,565	181,937
Convertible Debt, Noncurrent	0
Deferred Compensation Liability, Classified, Noncurrent	17,421	14,981
Deferred Tax Liabilities, Noncurrent	762	11,444
Due to Affiliate, Noncurrent	0	0
Other Liabilities, Noncurrent	2,963	1,099
Temporary Equity, Redemption Value	2,183	8,864
Total Core Laboratories N.V. shareholders' equity	42,613	132,509
Stockholders' Equity Attributable to Noncontrolling Interest	0	0
TOTAL EQUITY	42,613	132,509
TOTAL LIABILITIES AND EQUITY	195,507	350,834
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Cash and Cash Equivalents, at Carrying Value	9,183	34,106	14,059	11,999
Accounts Receivable, Net	124,718	121,079
Inventory, Net	38,244	29,852
Prepaid Expense and Other Assets	12,660	11,657
TOTAL CURRENT ASSETS	184,805	196,694
Property, Plant and Equipment, Net	84,205	83,084
Intangible Assets And Goodwill	99,988	100,053
Due from Affiliates	397,713	242,754
Equity Method Investments	1,596,076	1,567,416
Deferred Tax Assets, Net, Noncurrent	5,978	6,436
Other Assets Noncurrent less Investments	3,323	2,619
TOTAL ASSETS	2,372,088	2,199,056
Accounts Payable, Current	43,389	39,230
Convertible Debt, Current	0	0
Accrued Liabilities, Current	51,810	55,559
TOTAL CURRENT LIABILITIES	95,199	94,789
Convertible Debt, Noncurrent	0
Deferred Compensation Liability, Classified, Noncurrent	104	101
Deferred Tax Liabilities, Noncurrent	867	0
Due to Affiliate, Noncurrent	133,012	95,797
Other Liabilities, Noncurrent	20,579	17,615
Temporary Equity, Redemption Value	0	0
Total Core Laboratories N.V. shareholders' equity	2,119,188	1,987,905
Stockholders' Equity Attributable to Noncontrolling Interest	3,139	2,849
TOTAL EQUITY	2,122,327	1,990,754
TOTAL LIABILITIES AND EQUITY	2,372,088	2,199,056
Consolidation, Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Cash and Cash Equivalents, at Carrying Value	0	0	0	0
Accounts Receivable, Net	0	0
Inventory, Net	0	0
Prepaid Expense and Other Assets	0	0
TOTAL CURRENT ASSETS	0	0
Property, Plant and Equipment, Net	0	0
Intangible Assets And Goodwill	0	0
Due from Affiliates	(505,618)	(429,448)
Equity Method Investments	(2,161,801)	(2,120,414)
Deferred Tax Assets, Net, Noncurrent	(1,629)	(9,246)
Other Assets Noncurrent less Investments	0	0
TOTAL ASSETS	(2,669,048)	(2,559,108)
Accounts Payable, Current	0	0
Convertible Debt, Current	0	0
Accrued Liabilities, Current	0	0
TOTAL CURRENT LIABILITIES	0	0
Convertible Debt, Noncurrent	0
Deferred Compensation Liability, Classified, Noncurrent	0	0
Deferred Tax Liabilities, Noncurrent	(1,629)	(9,246)
Due to Affiliate, Noncurrent	(505,618)	(429,448)
Other Liabilities, Noncurrent	0	0
Temporary Equity, Redemption Value	0	0
Total Core Laboratories N.V. shareholders' equity	(2,161,801)	(2,120,414)
Stockholders' Equity Attributable to Noncontrolling Interest	0	0
TOTAL EQUITY	(2,161,801)	(2,120,414)
TOTAL LIABILITIES AND EQUITY	$ (2,669,048)	$ (2,559,108)

XML



Condensed Consolidating Financial Information Income Statement (Details) (USD $) In Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Condensed Financial Statements, Captions [Line Items]
Revenues	$ 225,785	$ 198,902	$ 432,518	$ 387,239
Revenue from Related Parties	0	0	0	0
Earnings (loss) from consolidated affiliates	0	0	0	0
Total Revenue	225,785	198,902	432,518	387,239
Costs of Services and Goods Sold Excluding Depreciation	152,273	128,917	289,023	254,505
Net income	40,384	34,362	86,376	66,648
Loss on exchange of Senior Exchangeable Notes	210	0	839	0
General and Administrative Expense, Excluding Depreciation	9,757	9,211	19,281	15,591
Depreciation and amortization	5,805	5,766	11,636	11,520
Net Income (Loss) Attributable to Non-controlling Interest	(67)	146	(365)	227
Other (income), net	147	1,288	(1,724)	490
OPERATING INCOME	57,803	53,720	114,302	105,133
Interest Expense	2,499	4,114	4,859	8,173
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	55,094	49,606	108,604	96,960
Income Tax Expense (Benefit)	14,710	15,244	22,228	30,312
Net income attributable to Core Laboratories N.V.	40,451	34,216	86,741	66,421
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	0	0	0	0
Revenue from Related Parties	409	379	769	667
Earnings (loss) from consolidated affiliates	48,014	37,709	86,708	72,898
Total Revenue	48,423	38,088	87,477	73,565
Costs of Services and Goods Sold Excluding Depreciation	264	322	558	712
Net income	40,451	34,216	86,741	66,421
Loss on exchange of Senior Exchangeable Notes	0	0	0
General and Administrative Expense, Excluding Depreciation	1,971	2,147	4,615	4,314
Depreciation and amortization	0	0	0	0
Net Income (Loss) Attributable to Non-controlling Interest	0	0	0	0
Other (income), net	814	992	943	857
OPERATING INCOME	45,374	34,627	81,361	67,682
Interest Expense	0	0	0	0
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	45,374	34,627	81,361	67,682
Income Tax Expense (Benefit)	4,923	411	(5,380)	1,261
Net income attributable to Core Laboratories N.V.	40,451	34,216	86,741	66,421
Consolidation, Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	0	0	0	0
Revenue from Related Parties	(37,561)	(43,449)	(83,358)	(83,833)
Earnings (loss) from consolidated affiliates	(138,521)	(153,454)	(157,511)	(289,402)
Total Revenue	(176,082)	(196,903)	(240,869)	(373,235)
Costs of Services and Goods Sold Excluding Depreciation	0	0	0	0
Net income	(120,079)	(163,904)	(97,101)	(309,674)
Loss on exchange of Senior Exchangeable Notes	0	0	0
General and Administrative Expense, Excluding Depreciation	0	0	0	0
Depreciation and amortization	0	0	0	0
Net Income (Loss) Attributable to Non-controlling Interest	0	0	0	0
Other (income), net	(34,246)	(32,999)	(65,618)	(63,561)
OPERATING INCOME	(141,836)	(163,904)	(175,251)	(309,674)
Interest Expense	(21,757)	0	(78,150)	0
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	(120,079)	(163,904)	(97,101)	(309,674)
Income Tax Expense (Benefit)	0	0	0	0
Net income attributable to Core Laboratories N.V.	(120,079)	(163,904)	(97,101)	(309,674)
Subsidiaries Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	52,935	48,386	100,735	93,547
Revenue from Related Parties	6,314	7,619	11,695	12,206
Earnings (loss) from consolidated affiliates	0	0	0	0
Total Revenue	59,249	56,005	112,430	105,753
Costs of Services and Goods Sold Excluding Depreciation	26,698	25,237	51,997	50,221
Net income	3,474	8,639	(58,898)	16,507
Loss on exchange of Senior Exchangeable Notes	210	0	839
General and Administrative Expense, Excluding Depreciation	7,784	7,060	14,654	11,270
Depreciation and amortization	1,599	1,554	3,229	3,112
Net Income (Loss) Attributable to Non-controlling Interest	0	0	0	0
Other (income), net	3,664	3,411	6,609	5,002
OPERATING INCOME	19,504	18,743	35,941	36,148
Interest Expense	24,256	4,112	83,009	8,167
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	(4,962)	14,631	(47,907)	27,981
Income Tax Expense (Benefit)	(8,436)	5,992	10,991	11,474
Net income attributable to Core Laboratories N.V.	3,474	8,639	(58,898)	16,507
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	172,850	150,516	331,783	293,692
Revenue from Related Parties	30,838	35,451	70,894	70,960
Earnings (loss) from consolidated affiliates	90,507	115,745	70,803	216,504
Total Revenue	294,195	301,712	473,480	581,156
Costs of Services and Goods Sold Excluding Depreciation	125,311	103,358	236,468	203,572
Net income	116,538	155,411	155,634	293,394
Loss on exchange of Senior Exchangeable Notes	0	0	0
General and Administrative Expense, Excluding Depreciation	2	4	12	7
Depreciation and amortization	4,206	4,212	8,407	8,408
Net Income (Loss) Attributable to Non-controlling Interest	(67)	146	(365)	227
Other (income), net	29,915	29,884	56,342	58,192
OPERATING INCOME	134,761	164,254	172,251	310,977
Interest Expense	0	2	0	6
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	134,761	164,252	172,251	310,971
Income Tax Expense (Benefit)	18,223	8,841	16,617	17,577
Net income attributable to Core Laboratories N.V.	$ 116,605	$ 155,265	$ 155,999	$ 293,167

XML



Condensed Consolidating Financial Information Cash Flow (Details) (USD $) In Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Dec. 31, 2010	Dec. 31, 2009
Condensed Financial Statements, Captions [Line Items]
Proceeds from Sale of Productive Assets			$ 171	$ 125
Non-controlling interest - contributions			(895)	0
ProceedsFromInsuranceRecoveries			884
Payments of Dividends, Noncontrolling Interest			(240)	(181)
Cash and Cash Equivalents, Period Increase (Decrease)			(109,319)	(7,423)
Proceeds from Stock Options Exercised			241	295
Excess Tax Benefit from Share-based Compensation, Financing Activities			2,289	798
Payments of Debt Issuance Costs			(1,094)	0
Settlement of Warrants			(57,777)	0
Net Cash Provided by (Used in) Operating Activities			97,954	111,360
Payments of Dividends			(22,709)	(5,375)
Premiums on life insurance			(1,243)	(921)
Payments for Repurchase of Common Stock			(52,097)	(91,686)
Net Cash Provided by (Used in) Financing Activities			(194,969)	(96,149)
Net Cash Provided by (Used in) Investing Activities			(12,304)	(22,634)
Repayment of debt borrowings			(64,477)	0
Cash and Cash Equivalents, at Carrying Value	24,561	173,622	24,561	173,622	133,880	181,045
Capital expenditures	(7,605)	(6,541)	(11,984)	(12,696)
Payments to Acquire Intangible Assets			(132)	(142)
Payments to Acquire Businesses, Net of Cash Acquired			0	9,000
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Proceeds from Sale of Productive Assets			137	114
Non-controlling interest - contributions			(895)
ProceedsFromInsuranceRecoveries			884
Payments of Dividends, Noncontrolling Interest			(240)	(181)
Cash and Cash Equivalents, Period Increase (Decrease)			(24,923)	2,060
Proceeds from Stock Options Exercised			0	0
Excess Tax Benefit from Share-based Compensation, Financing Activities			0	0
Payments of Debt Issuance Costs			0
Settlement of Warrants			0
Net Cash Provided by (Used in) Operating Activities			(15,755)	12,047
Payments of Dividends			0	0
Premiums on life insurance			0	0
Payments for Repurchase of Common Stock			0	0
Net Cash Provided by (Used in) Financing Activities			655	(181)
Net Cash Provided by (Used in) Investing Activities			(9,823)	(9,806)
Repayment of debt borrowings			0
Cash and Cash Equivalents, at Carrying Value	9,183	14,059	9,183	14,059	34,106	11,999
Capital expenditures			(10,728)	(9,778)
Payments to Acquire Intangible Assets			(116)	(142)
Payments to Acquire Businesses, Net of Cash Acquired				0
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Proceeds from Sale of Productive Assets			0	0
ProceedsFromInsuranceRecoveries			0
Payments of Dividends, Noncontrolling Interest			0	0
Cash and Cash Equivalents, Period Increase (Decrease)			(1,922)	(41,619)
Proceeds from Stock Options Exercised			241	295
Excess Tax Benefit from Share-based Compensation, Financing Activities			2,289	798
Payments of Debt Issuance Costs			0
Settlement of Warrants			(57,777)
Net Cash Provided by (Used in) Operating Activities			128,131	54,349
Payments of Dividends			(22,709)	(5,375)
Premiums on life insurance			0	0
Payments for Repurchase of Common Stock			(52,097)	(91,686)
Net Cash Provided by (Used in) Financing Activities			(130,053)	(95,968)
Net Cash Provided by (Used in) Investing Activities			0	0
Repayment of debt borrowings			0
Cash and Cash Equivalents, at Carrying Value	9,240	32,379	9,240	32,379	11,162	73,998
Capital expenditures			0	0
Payments to Acquire Intangible Assets			0	0
Payments to Acquire Businesses, Net of Cash Acquired				0
Subsidiaries Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Proceeds from Sale of Productive Assets			34	11
ProceedsFromInsuranceRecoveries			0
Payments of Dividends, Noncontrolling Interest			0	0
Cash and Cash Equivalents, Period Increase (Decrease)			(82,474)	32,136
Proceeds from Stock Options Exercised			0	0
Excess Tax Benefit from Share-based Compensation, Financing Activities			0	0
Payments of Debt Issuance Costs			(1,094)
Settlement of Warrants			0
Net Cash Provided by (Used in) Operating Activities			(14,422)	44,964
Payments of Dividends			0	0
Premiums on life insurance			(1,243)	(921)
Payments for Repurchase of Common Stock			0	0
Net Cash Provided by (Used in) Financing Activities			(65,571)	0
Net Cash Provided by (Used in) Investing Activities			(2,481)	(12,828)
Repayment of debt borrowings			(64,477)
Cash and Cash Equivalents, at Carrying Value	6,138	127,184	6,138	127,184	88,612	95,048
Capital expenditures			(1,256)	(2,918)
Payments to Acquire Intangible Assets			(16)	0
Payments to Acquire Businesses, Net of Cash Acquired				9,000
Consolidation, Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Proceeds from Sale of Productive Assets			0	0
Non-controlling interest - contributions			0
ProceedsFromInsuranceRecoveries			0
Payments of Dividends, Noncontrolling Interest			0	0
Cash and Cash Equivalents, Period Increase (Decrease)			0	0
Proceeds from Stock Options Exercised			0	0
Excess Tax Benefit from Share-based Compensation, Financing Activities			0	0
Settlement of Warrants			0
Net Cash Provided by (Used in) Operating Activities			0	0
Payments of Dividends			0	0
Premiums on life insurance			0	0
Payments for Repurchase of Common Stock			0	0
Net Cash Provided by (Used in) Financing Activities			0	0
Net Cash Provided by (Used in) Investing Activities			0	0
Repayment of debt borrowings			0
Cash and Cash Equivalents, at Carrying Value	0	0	0	0	0	0
Capital expenditures			0	0
Payments to Acquire Intangible Assets			0	0
Payments to Acquire Businesses, Net of Cash Acquired				$ 0

XML



Statement of Income Six Months Ended (USD $) In Thousands, except Per Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
REVENUE:
Services	$ 169,756	$ 153,010	$ 322,870	$ 296,452
Product sales	56,029	45,892	109,648	90,787
Total Revenue	225,785	198,902	432,518	387,239
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below	112,001	96,411	212,733	191,768
Cost of product sales, exclusive of depreciation expense shown below	40,272	32,506	76,290	62,737
General and Administrative Expense, Excluding Depreciation	9,757	9,211	19,281	15,591
Depreciation	5,507	5,430	11,047	10,849
Amortization	298	336	589	671
Other (income), net	147	1,288	(1,724)	490
OPERATING INCOME	57,803	53,720	114,302	105,133
Loss on exchange of Senior Exchangeable Notes	210	0	839	0
Interest expense	2,499	4,114	4,859	8,173
Income before income tax expense	55,094	49,606	108,604	96,960
Income Tax Expense (Benefit)	14,710	15,244	22,228	30,312
Net income	40,384	34,362	86,376	66,648
Net Income (Loss) Attributable to Non-controlling Interest	(67)	146	(365)	227
Net income attributable to Core Laboratories N.V.	$ 40,451	$ 34,216	$ 86,741	$ 66,421
EARNINGS PER SHARE INFORMATION:
Basic earnings per share attributable to Core Laboratories N.V.	$ 0.88	$ 0.77	$ 1.90	$ 1.48
Diluted earnings per share attributable to Core Laboratories N.V.	$ 0.83	$ 0.71	$ 1.77	$ 1.40
Cash dividends per share	$ 0.25	$ 0.06	$ 0.50	$ 0.12
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	45,945	44,651	45,587	44,743
Diluted	48,662	47,957	48,942	47,396

XML



Statement of Cash Flows Statement (USD $) In Thousands	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Net income	$ 86,376	$ 66,648
Net (recovery) provision for doubtful accounts	40	811
Provisions for inventory obsolescence	357	298
Equity in earnings of affiliates	(117)	(239)
Stock-based compensation	5,923	3,836
Depreciation and amortization	11,636	11,520
Non-cash interest expense	4,144	7,735
Gain on sale of assets	(138)	8
Gain on insurance recovery	(779)	0
Loss on exchange of Senior Exchangeable Notes	839	0
Realization of pension obligation	152	171
Increase in value of life insurance policies	(685)	765
Deferred income taxes	(10,735)	(8,822)
Accounts receivable	(5,627)	(4,618)
Inventories	(8,886)	(1,876)
Prepaid expenses and other current assets	1,055	23,896
Other assets	(623)	(540)
Accounts payable	8,639	6,519
Accrued expenses	(2,080)	7,698
Other long-term liabilities	8,463	(2,450)
Net cash provided by operating activities	97,954	111,360
Capital expenditures	(11,984)	(12,696)
Payments to Acquire Intangible Assets	(132)	(142)
Business Acquisitions	0	(9,000)
Proceeds from sale of assets	171	125
Proceeds from insurance recovery	884	0
Premiums on life insurance	(1,243)	(921)
Net cash used in investing activities	(12,304)	(22,634)
Repayment of debt borrowings	(64,477)	0
Proceeds from Stock Options Exercised	241	295
Excess Tax Benefit from Share-based Compensation, Financing Activities	2,289	798
Payments of Debt Issuance Costs	(1,094)	0
Settlement of Warrants	(57,777)	0
Non-controlling interest - contributions	895	0
Payments of Dividends, Noncontrolling Interest	(240)	(181)
Payments of Dividends	(22,709)	(5,375)
Payments for Repurchase of Common Stock	(52,097)	(91,686)
Net cash used in financing activities	(194,969)	(96,149)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(109,319)	(7,423)
CASH AND CASH EQUIVALENTS, beginning of period	$ 133,880	$ 181,045

XML



Significant Accounting Policies Level 1 (Notes)

6 Months Ended

Jun. 30, 2011

BASIS OF PRESENTATION [Abstract]

Basis of Presentation and Significant Accounting Policies [Text Block]

BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements include the accounts of Core Laboratories N.V. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP") for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP and should be read in conjunction with the financial statements and the summary of significant accounting policies and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2010.

Core Laboratories N.V. uses the equity method of accounting for investments in which it has less than a majority interest and over which it does not exercise control. Non-controlling interest has been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned.  In the opinion of management, all adjustments considered necessary for the periods presented have been included in these financial statements.  Furthermore, the operating results presented for the three and six months ended June 30, 2011 may not necessarily be indicative of the results that may be expected for the year ended December 31, 2011.

Core Laboratories N.V.'s balance sheet information for the year ended December 31, 2010 was derived from the 2010 audited consolidated financial statements but does not include all disclosures in accordance with U.S. GAAP.

Certain reclassifications were made to prior period amounts in order to conform to the current period presentation.  These reclassifications had no impact on the reported net income for the three and six month periods ended June 30, 2011.

References to "Core Lab", "we", "our" and similar phrases are used throughout this Quarterly Report on Form 10-Q and relate collectively to Core Laboratories N.V. and its consolidated subsidiaries.

XML



Inventories (Notes)

6 Months Ended

Jun. 30, 2011

INVENTORIES [Abstract]

Inventory Disclosure [Text Block]

INVENTORIES

Inventories consist of the following (in thousands):

	June 30, 2011		December 31, 2010
	(Unaudited)
Finished goods	$	31,843	$	24,476
Parts and materials	8,716		6,727
Work in progress	1,949		2,776
Total inventories, net	$	42,508	$	33,979

We include freight costs incurred for shipping inventory to customers in the Cost of Sales line of the Consolidated Statements of Operations.

XML



Goodwill and Intangibles

6 Months Ended

Jun. 30, 2010

GOODWILL AND INTANGIBLES [Abstract]

Intangible Assets Disclosure [Text Block]

GOODWILL AND INTANGIBLES

We account for intangible assets with indefinite lives, including goodwill, in accordance with the applicable accounting guidance, which requires us to evaluate these assets for impairment annually, or more frequently if an indication of impairment has occurred.  Based upon our most recent evaluation, we determined that goodwill is not impaired.  We amortize intangible assets with a defined term on a straight-line basis over their respective useful lives.

In 2010, we acquired fracture diagnostics assets for $9.0 million in cash.  The acquisition was recorded in the Production Enhancement business segment and resulted in an increase of $5.6 million in goodwill and an increase of $3.2 million in intangible assets.  The intangible assets will be amortized over a period of 36 to 60 months.